

HUTCHISON CHINA MEDITECH

Corporate Presentation

December 2019 AIM/Nasdaq: HCM





Safe harbor statement & disclaimer

The performance and results of operations of the Chi-Med Group contained within this presentation are historical in nature, and past performance is no guarantee of future results.

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words like "will," "expects," "anticipates," "intends," "plans," "believes," "estimates," "pipeline," "could," "potential," "believe," "first-in-class," "best-in-class," "designed to," "objective," "guidance," "pursue," or similar terms, or by express or implied discussions regarding potential drug candidates, potential indications for drug candidates or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that any of our drug candidates will be approved for sale in any market, or that any approvals which are obtained will be obtained at any particular time, or that any such drug candidates will achieve any particular revenue or net income levels. In particular, management's expectations could be affected by, among other things: unexpected regulatory actions or delays or government regulation generally; the uncertainties inherent in research and development, including the inability to meet our key study assumptions regarding enrollment rates, timing and availability of subjects meeting a study's inclusion and exclusion criteria and funding requirements, changes to clinical protocols, unexpected adverse events or safety, quality or manufacturing issues; the inability of a drug candidate to obtain regulatory approval in different jurisdictions or gain commercial acceptance after obtaining regulatory approval; glo

In addition, this presentation contains statistical data, third-party clinical data and estimates that Chi-Med obtained from industry publications and reports generated by third-party market research firms, including Frost & Sullivan, QuintilesIMS/IQVIA, independent market research firms, clinical data of competitors, and other publicly available data. All patient population, market size and market share estimates are based on Frost & Sullivan or QuintilesIMS/IQVIA research, unless otherwise noted. Although Chi-Med believes that the publications, reports, surveys and third-party clinical data are reliable, Chi-Med has not independently verified the data and cannot guarantee the accuracy or completeness of such data. You are cautioned not to give undue weight to this data. Such data involves risks and uncertainties and are subject to change based on various factors, including those discussed above.

Nothing in this presentation or in any accompanying management discussion of this presentation constitutes, nor is it intended to constitute or form any part of: (i) an invitation or inducement to engage in any investment activity, whether in the United States, the United Kingdom or in any other jurisdiction; (ii) any recommendation or advice in respect of any securities of Chi-Med; or (iii) any offer for the sale, purchase or subscription of any securities of Chi-Med.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither Chi-Med, nor any of Chi-Med's advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially.

All references to "Chi-Med" as used throughout this presentation refer to Hutchison China MediTech Limited and its consolidated subsidiaries and joint ventures unless otherwise stated or indicated by context. This presentation should be read in conjunction with Chi-Med's results for the six months ended June 30, 2019 and Chi-Med's other SEC filings, copies of which are available on Chi-Med's website (<u>www.chi-med.com</u>).

Use of Non-GAAP Financial Measures - This presentation includes certain non-GAAP financial measures. Please see the appendix slides titled "Non-GAAP Financial Measures and Reconciliation" for further information relevant to the interpretation of these financial measures and reconciliations of these financial measures to the most comparable GAAP measures.



Agenda

1	Company Overview	P4
2	Operating Highlights	P12
3	Financial Highlights, Cash & Guidance	P44
4	Summary	P47
5	Appendix	P52







Building a global science-focused biopharma company from an established base in China...






Global Innovation

- 5 clinical drug candidates in US/EU development
- Building global clinical development footprint
- World-class ~490-person scientific team

China Oncology



- Elunate[®] (fruquintinib capsules) first ever homegrown cancer drug launched in China^[1]
- 8 oncology assets in China development




Existing China Business

- Cash generative China Commercial Platform
- Platform for future innovative drug launches

[1] China-discovered novel oncology drug to receive unconditional NDA approval in China.



Proven innovation & commercial operations



[1] Headcount as of Oct 30, 2019; Chem. = Chemistry; DMPK = Drug, Metabolism, & Pharmacokinetics; Tox. = Drug Safety Evaluation; QA: Quality Assurance; Mfg. = Manufacturing; Reg. = Regulatory; BD = Business Development.

6

Portfolio summary Multiple waves of innovation – progressing rapidly




Dose Finding / Safety Run-In	Proof-of-Concept	Registration Intent	Marketed
Fruquintinib + Tyvyt (PD-1) Solid Tumors ^[1]	Savolitinib MET Exon 14 deletion NSCLC	Savo + Tagrisso (SAVANNAH) 2L/3L Tagrisso-refractory MET+ NSCLC	Elunate (Fruquintinib capsules) ≥3L Colorectal cancer
Surufatinib + Tuoyi (PD-1) Solid Tumors ^[1]	Savo / Savo + Imfinzi (CALYPSO) x2: PRCC & cCRCC	Savolitinib MET Exon 14 deletion NSCLC	SXBX ^[3] Pills Coronary artery disease
HMPL-523 (Syk) Indolent NHL ^[2]	Savolitinib (VIKTORY) MET+ Gastric cancer	Fruquintinib + Taxol (FRUTIGA) 2L Gastric cancer	>10 other Rx / OTC drugs
HMPL-689 (ΡΙ3Κδ) Indolent NHL	Savolitinib (CCGT 1234B) MET+ Prostate cancer	Surufatinib (SANET-p) Pancreatic NET	
Fruquintinib + Tyvyt (PD-1) Solid tumors ^[1]	Fruquintinib 3L/4L Colorectal cancer [1]	Surufatinib (SANET-ep) Non-Pancreatic NET	
Fruquintinib + genolimzumab (PD-1) Solid tumors	Surufatinib 2L Pancreatic NET	Surufatinib 2L Biliary Tract cancer	
Surufatinib + Tuoyi (PD-1) Solid tumors	Savolitinib + Iressa 2L 1 st Gen EGFR TKI ref. NSCLC		
Surufatinib + Tyvyt (PD-1) Solid tumors	Fruquintinib + Iressa 1L EGFRm+ NSCLC		
HMPL-453 (FGFR1/2/3) Solid tumors	HMPL-523 Indolent NHL		Global Innovation
	HMPL-523 + azacitidine AML		
	HMPL-523 Immune thrombocytopenia purpura		China Oncology Existing China Business
	HMPL-689 Indolent NHL		
	Epitinib Glioblastoma		IN TRANSITION

[1] In planning / imminent; [2] Proof-of-concept in Australia; [3] SX8X = She Xiang Bao Xin (cardiovascular); [4] Drugs licensed from third parties. Targets: Savolitinib = NET; Fruquintinib = VEGFR1/2/3; Surufatinib = VEGFR1/2/3; / FGFR1 / CSF-1R; HMPL-689 = PI3K8; Epitinib = EGFRm in the brain; Theliatinib = EGFR wild-type; HMPL-453 = FGFR1/2/3. Indications: NHL = Non-Hodgkin's Lymphoma; NET = Neuroendocrine tumors; RCC = Renal cell carcinoma; AML = Acute myeloid leukemia; ITP = Immune thrombocytopenia; NSCLC = Non-small cell lung cancer.



Potential upcoming events


progress.



* submission to scientific conference; ** subject to supportive data; Targets: Savolitinib = MET; Fruquintinib = VEGFR1/2/3; Surufatinib = VEGFR1/2/3 / FGFR1 / CSF-1R; HMPL-523 = Syk; HMPL-689 = PI3Kδ; Indications: NHL = Non-Hodgkin's Lymphoma; NET = Neuroendocrine tumors; RCC = Renal cell carcinoma; NSCLC = Non-small cell lung cancer.

Global clinical drug portfolio (1/2)






MET = mesenchymal epithelial transition receptor, VEGFR = vascular endothelial growth factor receptor, NSCLC = non-small cell lung cancer, RCC = renal cell carcinoma, PRCC = papillary RCC, CRC = colorectal cancer; [1] Efficacy Evaluable Patients. Data cut-off: Oct. 10, 2017; [2] Dosed to-date = patients in all clinical trials (treatment & placebo); [3] Phase II registration intent study subject to regulatory discussions.

Global clinical drug portfolio (2/2)






[1] Dosed to-date = patients in all clinical trials (treatment & placebo); [2] American Society of Hematology. Blood, vol. 132 no. Suppl 1 5324 (Nov 2018); VEGFR = vascular endothelial growth factor receptor, FGFR1 = fibroblast growth factor receptor 1, CSF-1R = colony stimulating factor-1 receptor, Syk = spleen tyrosine kinase, PI3K\delta = Phosphatidylinositol-3-Kinase delta, pNET = pancreatic neuroendocrine tumors, ep-NET = non-pancreatic neuroendocrine tumors, AML = acute myeloid leukemia, FL = follicular lymphoma, CLL = chronic lymphocytic leukemia, SLL = small lymphocytic leukemia.



Important milestones in Chi-Med's evolution



[1] Based on aggregate Non-GAAP revenues and net income / (loss) of consolidated subsidiaries and non-consolidated joint ventures of Commercial Platform.







NET = neuroendocrine tumors; combos = concurrent treatment with other cancer therapies; EGFR-TKI = epidermal growth factor receptor mutation tyrosine kinase inhibitor; NSCLC = non-small cell lung cancer.

Recent Operating Highlights

Surufatinib

- **Positive China Phase III** and **NDA accepted** non-pancreatic NET un-blinded a year ahead of schedule;
- Initiated Phase IIb/III biliary tract cancer; & Phase I for PD-1 combos.

Elunate[®] (fruquintinib capsules)

- Early progress on Elunate[®] 3L colorectal cancer in China;
- Cleared Phase III interim analysis 2L gastric cancer (FRUTIGA);
- Initiated Phase I for PD-1 combos.

Savolitinib

- Reached enrollment goal on Phase II registration study MET Exon 14 deletion NSCLC;
- AstraZeneca collaboration leading global position in EGFR-TKI resistant NSCLC;
- Emerging signal for savolitinib/Imfinzi® (PD-L1) combo renal cell carcinoma.





13



congress



Other Recent Operating Highlights



B-cell malignancies / non-Hodgkin's lymphoma

- HMPL-523 (Syk) >150 patients dosed in China/Australia Phase I/Ib; to guide registration strategy in late 2019;
- S HMPL-689 (PI3K δ) **-** Phase II dose selected in China & expansion underway;
- **US/EU Phase I 1st patient dosed** for both HMPL-523 & HMPL-689.

Organization

- S Accelerating expansion of New Jersey-based international C&R operations;
- Establishing China oncology commercial team ~70 commercial staff in place, focused on medical affairs & preparation for potential surufatinib launch.

Discovery

3

IND submission on HMPL-306 – an isocitrate dehydrogenase (IDH) 1/2 inhibitor.



Mechanism of Action

<u>Anti-angiogenesis</u>: cut off <u>blood flow to tumor</u> (VEGFR/FGFR).

Immunotherapy: inhibit expression of tumorassociated macrophages which cloak cancer cells from T-cell attack (CSF-1R). Tumor-associated macrophages

T-cells

2a Surufatinib: angio-immuno kinase inhibitor

Angiogenesis

What are neuroendocrine tumors ("NET")? ~2% of all malignancies. Tumor begins in the specialized cells of the body's

- Tumor begins in the specialized cells of the body's neuroendocrine system. Cells have traits of both hormone-producing endocrine cells & nerve cells.
- Found throughout the **body's organs**. Most NETs take years to develop but some can grow fast.

S Hormone-related symptoms [1]

Functional NETs (~8-35% of patients) release hormones / peptides causing symptoms like diarrhea & flushing; Non-functional NETs have no symptoms.


S Differentiation & biomarkers for grading:


- Well differentiated: look like healthy cells grow slowly; Poorly differentiated: look less like healthy cells - grow quickly;
- Mitotic count Mitosis is process by which tumor cells grow & divide; Ki-67 index – Ki-67 a protein that increases as cells divide.

[1] Dasari A, et al.: Trends in the Incidence, Prevalence, & Survival Outcomes in Patients With Neuroendocrine Tumors in the U.S., JAMA Oncol. 2017;3(10):1335-1342;

[2] www.cancer.net (patient information from ASCO) - NET is a subtype of neuroendcrine neoplasms, NENs); [3] IQVIA 2019; [4] Gastroentero-pancreatic neuroendocrine tumors = GEP NETs.

NET epidemiology – highly fragmented







Surufatinib

Overview of NET - ~170,000 patients in the U.S. [1][2][3]

High-level NET landscape Long-term disease – rapid deterioration in later stages ^{[1][2][3]}



Grade 1 (G1) NET Localized / Regional

mOS:

16.2 yrs.

Well Differentiated

Ki-67 Index ≤2; Mitotic Count <2

~8-35% NET patients -Functional NET -

Hormone related symptoms:

> 94% flushing 78% diarrhea 53% heart plaque 51% cramping

Symptoms allow early diagnosis


Somatostatin Analogue

Treatment - modulate/ control symptoms related to hormone overproduction & tumor growth:

Octreotide: \$1.6b revenue (2018) Lanreotide: \$1.0b revenue (2018) G1/2 - Advanced NET Regional / Distant

∽60% NET patients - first diagnosis at advanced disease stage -Mostly non-Functional NET - TKIs^[4]; chemo/ radiotherapy

MOS: 8.3 yrs.



Moderately Differentiated Ki-67 Index 3-20; Mitotic Count 2-20 **G3 - NET/NEC** Distant

No approved treatments - exploring *I/O*^[5]

+ TKI combos



Poorly Differentiated *Ki-67 Index >20; Mitotic Count >20*

[1] Arvind Desari et. al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the US, JAMA Oncol. 2017;3(10):1335-1342; [2] Van Cutsem et al. ESMO - Neuroendocrine Tumors Diagnostic & Therapeutic Challenges; [3] mOS = median overall survival; [4] TKIs = Tyrosine Kinase Inhibitors; [5] I/O = Immuno oncology/immunotherapy

G1/2 Advanced NET^[1] *(Ki-67 Index 0-20)* Global opportunity in lung/other NETs & China wide-open



Site		est. %	Octreotide	Lanreotide	¹⁷⁷ Lu-Dotatate	Streptozocin	Sunitinib	Everolimus	Surufatinib
Disease status			Treatment naïve	Stable disease	Progressed in past 3 yrs.	Historical	Progressed in past 12 mo.	Progressed in past 6 mo.	Progressed in past 12 mo.
	Stomach	7%		CLARINET ^[2]	Historical Ph.II SSR over expression			RADIANT-4 ^[3]	SANET-ep
	Small bowel/ Appendix	9%	PROMID	CLARINET ^[2]	NETTER-1			RADIANT-4 ^[3]	SANET-ep
GI Tract	Colon & Rectum	31%		CLARINET ^[2]	Historical Ph.II ssR over expression			RADIANT-4 ^[3]	SANET-ep
	Pancreas	6%		CLARINET ^[2]	Historical Ph.II SSR over expression	Historical	PHASE III	RADIANT-3 ^[4]	SANET-p H1 2020 interim
	Lung	20%						RADIANT-4 ^[3]	SANET-ep
Other	Other	∽17%							SANET-ep
	Unknown 1°	∽10%						RADIANT-4 ^[3]	SANET-ep

[1] Yao ESMO 2019; [2] CLARINET approved only for Ki-67 Index <10 (i.e. est. ~50% of G1/G2); [3] Everolimus approved in non-Functional NET (~60% pNET; 90% Lung NET; majority mid-gut/small bowel NET); [4] RADIANT-3 – Progressed in past 12 months.



China


Global (ex-China)

SANET-ep vs. RADIANT-4 – cannot compare SANET-ep broader range of tumor origins & later-stage patients



Tumor Origin	Gastrointestinal Tract Rectum Stomach Small Intestine Other Organ Site Thymus Liver Mediastinum Adrenal Gland Other Unknown Origin	Asia/China Extra- Pancreatic NET Tsai et al. 2013 58% 30% 7% 19% 3% 22%	SANET-ep (n=198) (surufatinib vs placebo) 47% 27% 10% 8% 3% 12% 28% 7% 6% 6% 6% 6% 2% 8% 14%	Gastrointestinal Tract Rectum Stomach Small Intestine Other Gr Lung Thymus Unknown Origin	U.S. Extra- Pancreatic NET Yao et al. 2008 50% 33% 8% 6% 4% 21%	RADIANT-4 (n=302) (everolimus vs placebo) 58% 13% 4% 34% 7% 30% 1%	SANET-ep Enrolled more pts with poor prognosis. Survival Rate <u>Primary Site</u> mOS @ 5-yr Rectum 2.8y 28% Stomach 2.4y 32% Stomach 2.4y 32% Small Intestine 8.6y 69% RADIANT-4 Did not enrol other extra-pancreatic NET organ sites incl. but not limited to Throat Thyroid Kidney Ovary Mediastinum Adrenal gland Retroperitoneal Ampula vater Parathyroid gland Carotid body Liver	p
Pathology grade	Grade 1 Grade 2		16% 84%			65%	Line _ coverage.	
ECOG PS 0:1	PS 0 (treatment : control) PS 1 (treatment : control)		60% (56% : 67%) 40% (44% : 33%)			74% (73% : 75%) 26% (27% : 26%)	SANET-ep	
Prior systemic treatment	Any Prior Treatment Chemotherapy Targeted therapy Somatostatin Analogues		67% 40% 10% 32%			61% 25% none 55%	Later-stage patients , more heavily pre- treated (incl. with targeted therapy) & weaker physical status.	
Multiple organ involvement		66% with multiple organ 76% had liver metastasis 47% had lymph nodes m 33% had bone metastasi 26% had lung metastasis	etastasis s		79% had liver metastasis 43% had lymph nodes me 19% had bone metastasis 22% had lung metastasis		Likely due to later diagnosis in China & availability of everolimus.	

Source: Xu et al, ESMO 2019 #LBA76; Yao et al, Lancet 2016 387(10022) 968-77; Yao et al, JAMA Oncol 2017 3(10) 1335-42; Excludes 7% pancreatic NET in US series and 6% in Asia series; Colon-rectum in Tsai et al. (2013) report; Colon approximately 8% in Asian series (Shebani KO et al. (1999)); Colon-rectum in Yao et al. (2008) report; Colon approximately 4-7% in US/EU series (Niederle B et al. (2016)).



SANET-ep Primary (1°) endpoint was Investigator mPFS BIIRC ^[4] mPFS for supportive analysis not 1° or 2° endpoint

RADIANT-4 Primary (1°) endpoint was BIIRC ^[4] mPFS Investigator mPFS not 1° or 2° endpoint


[1] ESMO 2019 LBA#76; [2] Yao et al. "Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4)" Lancet. 2016 Mar 5;387(10022):968-977. doi: 10.1016/S0140-6736(15)00817-X. Epub 2015 Dec 17; [3] P-value is obtained from the stratified one-sided log-rank test; Hazard ratio is obtained from stratified Cox model; CI, confidence interval; HR, hazard ratio; [4] BIIRC = Blinded Independent Image Review Committee (Central).

Very different mechanism of action




Everolimus inhibits **mTOR** and blocks the effects caused by the loss of certain genes thereby reducing cell growth, proliferation, and angiogenesis.

Surufatinib inhibits VEGFR1/2/3 and FGFR1 blocking vascular cell growth and angiogenesis; as well as CSF-1R which limits the production of TAMs which cloak the cancer cell from T-Cell attack.



Surufatinib efficacy post everolimus failure U.S. Phase Ib (n=15) - pNET duration of treatment






Encouraging preliminary surufatinib efficacy post everolimus failure – different MOA^[1]

Surufatinib – China NET Non-Pancreatic NET estimated to represent ~80% of China NET



Epidemiology – *China NET & BTC patient populations*



NET is major unmet medical need in China – with long treatment duration

[1] Current estimated Prevalence to Incidence ratio in China at 4.4, lower than U.S. 7.4 ratio due to lower access to treatment options.[2] NRDL pricing references calculations assume exchange rate of RMB6.74 per US\$1.

Surufatinib – China NET NET potential ~\$100-120m/yr. – under treated/diagnosed



Competitive landscape – *China NET treatments*^[1]

Brand	Indication/s	Launched		2017	2018	01-2019
SUTENT®	Pancr. NET	2007	Sales (US\$ million)	27	24	7
<i>(sunitinib - VEGFR)</i> Pfizer	(& GIST/RCC)		List Price (US\$/month)	4,455	NRDL Oct-18	2,007
AFINITOR[®]	Pancr. NET	2013	Sales (US\$ million)	9	13	3
<i>(everolimus – mTOR)</i> Novartis	(& 2L RCC)		List Price (US\$/month)	NRDL Jul-17	1,320	1,320
SANDOSTATIN LAR®	GEP-NENS ^[3]	2003	Sales (US\$ million)	14	15	5
<i>(octreotide – SSA</i> ^[2]) Novartis			List Price (US\$/month)	1,169	NRDL Oct-18	835

Pancreatic-NET market est. ~\$10-15m/yr. - Non-Pancreatic NET market ~5-10X

1° endpoint: median PFS. Placebo Well tolerated 2:1 😋 2° endpoints: ORR, DCR, SANET-D DOR, TTR, OS. Surufatinib SANET-p Interim Analysis **Pancreatic NET** R in (H1 2020. (Planned N=195) Placebo 2:1 ...preparing for our first China launch... 2019 2020 Est. Late 2020 04'19-Sep 29, '19 - SANET-ep Jun 14, '19 - SANET-eD **Interim Analysis** Presentation at ESMO China launch NDA Accepted • Study stopped early, a year • mPFS primary endpoint • Tumor control secondary ahead of schedule. **Building out Oncology Full China** Current endpoints • Pre-NDA meeting with CDE. Sales, Mkt., & Med. Aff. Org. **~70 ppl**. coverage Placebo control 25

Two Phase III neuroendocrine tumor ("NET") registration studies...

R

Surufatinib

Potentially our first un-partnered oncology drug launch

SANET-ep

Non-pancreatic NET

(Actual N=198)

Surufatinib

25 China sites.

Data presentation at ESMO 2019

Met all efficacy endpoints

Surufatinib Other ongoing trials

Phase IIb/III study in 2L BTC


- First patient dosed in March 2019;
- Nearly all planned sites now activated;
- Interim analysis mid-2020, based on first 80 patients;
- Total enrollment ∽300 patients.

PD-1 collaborations

- With Junshi (Tuoyi[®]): Dose expansion in multiple tumor types to begin Q4 2019;
- With Innovent (Tyvyt®): Global studies in planning.

Ex-China development

- U.S. Phase Ib/II in P-NET & BTC initiated July 2018 NET enrollment complete;
- FDA End of Phase II meeting targeted for Q4 2019;
 - U.S. & Europe Phase III registration study expected to initiate in Q1 2020.














ELUNATE Fruquintinib Capsules



Epidemiology



Launch pricing ^[3]

Launch pricing (OOP [4]) ~US\$ 3,260 per cycle (RMB 21,966 per cycle) (one cycle 4 weeks)

Patient Access Program
Cycle 1: ~US\$ 3,260
Cycle 2: ~US\$ 3,260
Cycle 3: Free (PAP ^[5])
Cycle 4: Free (PAP ^[5])
Cycle 5: ~US\$ 3,260
Cycle 6 onwards: Free (PAP ^{[5}
Total OOP cost to patients
US\$ 9,800 (RMB 65,880)
Average Usage
~Avg 5 mths / 5.5 cycles

(to progression; 3.7 mo. mPFS^[6])

National Reimbursed Drug List (NRDL)

2019 NRDL released by China's National Healthcare Security Administration ("NHSA")

• Announced Nov. 28, 2019; effective Jan. 1, 2019

3rd-line colorectal cancer ("CRC")

- 8 newly listed oncology drugs, including Elunate[®]
- Reimburse 50-70% of patient costs under urban scheme


OOP costs for per cycle	BL CRC Patients	Urban Med. Insur. Scheme (UMI)	Non-UMI
Population <i>% China</i>		317m <i>23%</i>	1,053m <i>77%</i>
Elunate® (fruquintinib)	Pre-NRDL Post-NRDL 3L CRC Pts OOP	RMB21,966 7.938 2,381~<u>3</u>,969	RMB21,966 7.938 7,938
Stivarga® (regorafenib)	Pre-NRDL Post-NRDL 3L CRC Pts OOP	RMB30,240 16,464 4,939~8,232	RMB30,240 16,464 16,464

[1] W. Chen, R. Zheng et al, CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. Cancer Statistics in China, 2015. doi:10.3322/caac.21338. Epub 2016 Jan 25; [2] Frost & Sullivan; [3] Pricing figures represent retail prices paid per patient to Lilly; [4] OOP = out of pocket; [5] PAP = Patient Access Program, subject to qualification criteria; [6] mPFS = median Progression-Free Survival; [7] PRDL = Provincial Reimbursement Drug List; [8] End-2017, 14,968k people covered by Shanghai PRDL including 10,054k employees and 4,914k retirees; Total SH population 24,183k incl. 14,456k local residents & 9,727k external population; [9] pay for 3 cycles x RMB2,860/box x 3 weeks/box = RMB 25,740 (RMB:US\$ exchange rate of 6.74:1).

ELUNATE[®] H1 2019 performance Fruquintinib Capsules



Elunate[®] Performance



Elunate[®] early progress – PAP working but NRDL will provide greater access

[1] Royalties to Chi-Med in H2 2018 and H1 2019 of \$0.261m and \$1.715m, respectively; at the lowest tier royalty rate of 15%, this implies net sales from third parties to Lilly of \$1.7m and \$11.4m, respectively; at RMB:US\$ exchange rate of 6.87:1 and 6.74:1, respectively, this implies RMB sales of 12m and 77m, respectively; [2] Treatment cycle = 28 day, i.e. assume three x 7 capsule 5mg packs per cycle or five x 21 capsule 1mg packs per cycle; OOP = Out of pocket payment; PAP = Patient access program; [3] Sales of Elunate manufactured by Chi-Med to Eli Lilly.

ELUNATE[®] Fruquintinib Capsules China VEGFR landscape



Competitive landscape – *small molecule VEGFR TKIs*

Brand	Indication/s	Launch		2011	2012	2013	2014	2015	2016	2017	2018	01-2019
STIVARGA®	3L CRC /2L GIST	May 2017	Sales (US\$ million) [1]							5	21	20
<i>(regorafenib)</i> Bayer AG	2L HCC	Mar 2018	List Price (US\$/mo.)							4,368	NRDL Oct-18	2,352
NEXAVAR®	Unres. RCC & HCC		Sales (US\$ million) [1]	80	96	96	93	91	97	108	130	50
<i>(sorafenib)</i> Bayer AG	Diff. Thyroid can.		List Price (US\$/mo.)						7,250	NRDL Jul-17	3,610	3,610
SUTENT®	RCC, GIST, pNET	2007	Sales (US\$ million) [1]	9	33	41	21	26	29	27	24	7
<i>(sunitinib)</i> Pfizer			List Price (US\$/mo.) ^[4]							5,544	NRDL Oct-18	2,498
INLYTA®	2L adv. RCC	2015	Sales (US\$ million) [1]					3	12	16	13	5
<i>(axitinib)</i> Pfizer			List Price (US\$/mo.)							5,957	NRDL Oct-18	1,787
VOTRIENT®	RCC	2017	Sales (US\$ million) [1]							5	12	5
<i>(pazopanib)</i> Novartis			List Price (US\$/mo.)							7,891	NRDL Oct-18	2,348
AITAN®	3L Gastric can.	Dec 2014	Sales (US\$ million) ^[2]					∽45	∽126	219	258	~82
<i>(apatinib)</i> Hengrui			List Price (US\$/mo.)						2,870	NRDL Jul-17	1,810	1,810
FOCUSV®	3L NSCLC	June 2018	Sales (US\$ million) [3]								∽1 9 0	~83
<i>(anlotinib)</i> Sino Biopharn	ı		List Price (US\$/mo.)								NRDL Oct-18	981

Elunate® first 6 mo. sales progressing... relative to all MNC VEGFRi China launch sales ^[5]

[1] Frost & Sullivan; [2] Hengrui 2018 Annual report, dated on Feb 26, 2019; Goldman Sachs Research 2018 & GuoSen Securities research report July 20, 2017; [3] Sinobiopharm 2018 annual report/Citi Research May 2019. Note: Calculations assume at CER, using exchange rate of RMB6.74 per US\$1; [4] Sutent[®] price avg. pre-NRDL \$5,544 RCC/GIST, \$4,455 pNET; post-NRDL \$2,498/\$2,007; [5] MNC = multinationals, Nexavar[®] Yr.1 sales \$18.6m (2007) & Sutent[®] Yr.1 sales \$7.4m (2008).

ELUNATE Fruquintinib Capsules



	FRESCO ^[1] Mainland China		CONC	UR	CONC	UR	CORRECT	
Third-Line Metastatic Colorectal cancer			Chinese Patients (Mainland China, Hong Kong, Taiwan) ^[2]		Mainland China Taiwan, Vietnam		Global	
Treatment arms	Elunate®	Placebo	Stivarga ®	Placebo	Stivarga ®	Placebo	Stivarga [®]	Placebo
Patients (n)	278	138	112	60	136	68	505	255
Objective Response Rate, n (%)	4.7%	0.0%	3.6%	0.0%	4.4%	0.0%	1.0%	0.4%
Disease Control Rate, n (%)	62.2% +4	9.9 12.3%	45.5% +38	.8 6.7%	51.5% +44	.1 7.4%	41.0% +26	.1 14.9%
Median Progression-Free Survival (mPFS) (mo.)	3.7 +1	<mark>.9</mark> 1.8	2.0 +0.	3 1.7	3.2 +1.	5 1.7	1.9 + 0.	2 1.7
Median Overall Survival (mOS) (mo.)	9.3 +2	2.7 6.6	8.4 +2.	2 6.2	8.8 +2.	5 6.3	6.4 +1	4 5.0

Advantage for Elunate[®] efficacy vs. Stivarga[®] in Chinese metastatic **CRC** patients;

Advantage for Elunate[®] post **VEGF/EGFR** targeted therapy

- mOS: 7.69 mo. vs. 5.98 mo. placebo (HR 0.63 & p-value 0.012)
- mPFS: 3.65 mo. vs. 1.84 mo. placebo (HR 0.24 & p-value < 0.001)

Overall Survival subgroup analysis by Prior Treatment^[1]

3rd-line CRC efficacy advantage

100% Avastin prioruse

		Hazard Ratio (95% CI)	p-value
Overall	- -	0.65 (0.51, 0.83)	<0.001
with prior anti-VEGF therapy		0.68 (0.45, 1.03)	0.066
without prior anti-VEGF therapy	- - -	0.60 (0.45, 0.80)	<0.001
with prior anti-VEGF or anti-EGFR therapy		0.63 (0.46, 0.90)	0.012
without prior anti-VEGF or anti-EGFR therapy	_ _	0.63 (0.43, 0.86)	0.003
	0 0.5 1.0 1.	5 2.0	
	Favors Fruquintinib Favors	Placebo	

1] Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial; [2] Efficacy & safety of regorafenib monotherapy in Chinese patients with previously treated metastatic colorectal cancer: subgroup analysis of the CONCUR trial; R Xu.

Fruquintinib Capsules



	ELUNATE [®] Fruquintinib Capsules	Stivarga® (regorafenib) tablets
BIOCHEMICAL ACTIVITY	IC _{so} (nmol/L)	IC ₅₀ (nmol/L)
On-Target Kinases:		
VEGFR1	33	13
VEGFR2	35	4.2
VEGFR3	0.5	46
Off-Target Kinases:		
Ret	128	1.5
FGFR1	181	202
c-kit	458	7
PDGFRβ	>10,000	22
RAF-1	>10,000	2.5
B-RAF	>10,000	28
B-RAF ^{V600E}	>10,000	19

Stivarga® liver toxicity black-box warning:

→ Increased liver function test monitoring (weekly if elevated) & remedial dose interruption.

STIVARGA (regorafenib) tablets, oral Initial U.S. Approval: 2012

WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. • Severe and sometimes fatal hepatotoxicity has been observed in clinical trials. (5.1) • Monitor hepatic function prior to and during treatment. (5.1) • Interrupt and then reduce or discontinue Stivarga for hepatotoxicity as manifested

by elevated liver function tests or hepatocellular necrosis, depending upon

severity and persistence. (2.2)

	ELU Fruquintir	NATE [®] Nib Capsules	(regorafenib) tablets			
3 rd -Line Metastatic Colorectal cancer		FRESCO Study Mainland China ^[1]		R Study I, HK, Taiwan) ^[2]		
Treatment arms	Elunate®	Placebo	Stivarga [®]	Placebo		
Patients (n)	278	138	112	60		
≥G3 AE (Safety population)	61.1%	19.7%	69.6%	46.7%		
SAE (Safety population)	15.5%	5.8%	31.3%	26.7%		
VEGFR on-target related AEs:						
Hypertension \geq G3	21.2%	2.2%	12.5%	8.3%		
Hand-Foot Syndrome (Palmar-plantar), ≥G3	10.8%	0.0%	17.0%	0.0%		
Off-target (i.e. non-VEGFR) related AEs:			\frown			
Hypophosphatemia, ≥G3	0.0%	0.0%	8.0%	0.0%		
Hypokalemia, ≥G3	0.7%	0.7%	6.3%	0.0%		
Rash/desquamation, ≥G3	0.0%	0.0%	4.4%	0.0%		
Lipase increase, ≥G3	0.0%	0.0%	6.3%	1.7%		
Hepatic function (Liver function) AEs:						
ALT increased, ≥G3	0.7%	1.5%	7.1%	3.3%		
AST increased, ≥G3	0.4%	0.7%	8.9%	0.0%		
Blood bilirubin increased, ≥G3	1.4%	1.5%	8.9%	8.3%		
Tolerability:						
AE Leading to dose interruption	35.3%	10.2%	68.8%	25.0%		
AE Leading to dose reduction	24.1%	4.4%	23.2%	0.0%		
AE Leading to treatment discontinuation	15.1%	5.8%	14.3%	6.7%		

Toxicity limitations of Stivarga[®]

Elunate® superior safety - advantage especially for liver mets patients

[1] Treatment Related AEs (FRESCO study); [2] All AEs -- Efficacy & safety of regorafenib monotherapy in Chinese patients with previously treated metastatic CRC: subgroup analysis of the CONCUR trial; R Xu.; >G3 AEs in >4% of Patients. 32



Ongoing trials

Phase III in 2L gastric cancer (FRUTIGA)

- Passed first interim analysis by IDMC, trials continuing per IDMC recommendation;
- On track to complete enrollment Q2 2020.

PD-1 collaborations

- With Innovent (Tyvyt[®]): dose/regimen finding ongoing;
- With Genor (genolimzumab): dose escalation ongoing;
- Dose expansion expected to kick off starting Q4 2019.

Phase II in 1L NSCLC (in combination with Iressa®)

Study complete and to submit data for presentation at an upcoming scientific conference.







Innovent Biologics






AstraZeneca and Chi-Med Harnessing the power of Chinese Innovation



Savolitinib Biggest opportunity is MET+ NSCLC






[1] Primary drivers, based on aggregate rocelitinib/Tagrisso data published at 2016/2017 ASCO; [2] Research estimates; [3] company annual reports and Frost & Sullivan.

Savolitinib – MET Exon 14 deletion NSCLC^[1] Potential China NDA submission in 2020^[2]




4. Encouraging MET Exon14d NSCLC study China data at AACR 2019 ^[3]


- S 41 pts; 31 pts efficacy evaluable.
- 🕑 Promising antitumor activity.
- C Rapid, durable tumor response observed.
- S Anti-tumor activity observed in brain mets.
- Savolitinib generally well tolerated; most related 1 TEAEs were grade 1 or 2.



5. MET Exon14d NSCLC potential NDA filing 2020 ^[2]



6. Savolitinib monotherapy China market opportunity



[1] The trial is focused on patients with MET Exon 14 mutation who have failed prior systemic therapy, or are unable to receive chemotherapy, however the target patient population is intended to be all MET Exon 14 mutation patients; [2] We expect that the Phase II study of savolitinib in MET Exon 14d NSCLC would, if successful, be sufficient to support NDA submission; [3] Data cut-off Feb. 26, 2019. Lu S et al, CT031 - Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET Exon 14 skipping mutations. Presented at American Association of Cancer Research Annual Meeting 2019, Atlanta, GA, Mar. 31, 2019; [4] Center for Drug Evaluation of the National Medicinal Products Administration of China.

TATTON B & D data – efficacy Tagrisso[®] + savolitinib in EGFR TKI refractory NSCLC




	\langle	TATTON Part D osimertinib 80 mg + savolitinib 300 mg		
	Part B1 (n=69) Prior third-generation EGFR-TKI	Part B2 (n=51) No prior third-generation EGFR-TKI (T790M negative)	Part B3 (n=18) No prior third-generation EGFR-TKI (T790M positive)	Part D (n=36) No prior third-generation EGFR-TKI (T790M negative)
Objective response rate ,* % [95% CI] Complete response, % Partial response, %	30% [20, 43] 0 30%	65% [50, 78] 0 65%	67% [41, 87] 0 67%	64% [46, 79] 0 64%
Non-response, % Stable disease (≥ 6 weeks) Progressive disease Not evaluable	45% 10% 14%	24% 6% 6%	33% 0 0	28% 3% 6%
Disease control rate, #% [95% CI]	75% [64, 85]	88% [76, 96]	100% [81, 100]	92% [78, 98]
Median DoR, months [95% CI]	7.9 [4.0, 10.5]	9.0 [6.1, 22.7]	12.4 [2.8, NR]	8.0 [4.5, NR]
Median PFS, months [95% CI]	5.4 [4.1, 8.0]	9.0 [5.5, 11.9]	11.0 [4.0, NR]	9.1 [5.4, 12.9]

No reduction in efficacy with 300mg savo – SAVANNAH converted to 300mg dose

[1] Most patients were enrolled to Part B1, B2, B3 on 600 mg savolitinib, prior to weight-based dosing implementation, but following a protocol amendment in response to a safety signal of hypersensitivity, the final 21 patients enrolled in Part B were dosed with savolitinib by body weight as follows: patients who weighed \leq 55 kg (n=8) received 300 mg daily and those weighing >55 kg (n=13) received 600 mg daily; Best response data are for patients who had an opportunity to have two follow-up scans.; *Complete or partial response confirmed at \geq 4 weeks. #Disease control rate = confirmed complete response + confirmed partial response + stable disease at \geq 5 weeks.; CI, confidence interval; NR, not reached.

TATTON B & D data – ORR Tagrisso[®] + savolitinib in EGFR TKI refractory NSCLC






ORR = Objective Response Rate; EGFR = Epidermal Growth Factor Receptor; TKI = Tyrosine Kinase Inhibitor; [1] Most patients were enrolled to Part B1, B2, B3 on 600 mg savolitinib, prior to weight-based dosing implementation, but following a protocol amendment in response to a safety signal of hypersensitivity, the final 21 patients enrolled in Part B were dosed with savolitinib by body weight as follows: patients who weighed \leq 55 kg (n=8) received 300 mg daily and those weighing >55 kg (n=13) received 600 mg daily. 38

TATTON B & D data – PFS Tagrisso[®] + savolitinib in EGFR TKI refractory NSCLC






1.0

	Median PFS, months [95% CI]	Median (range) duration of follow-up in censored patients, months
Part B1 Prior third-generation EGFR-TKI; (600 mg ^[1] ; n=69)	5.4 [4.1, 8.0]	2.6 [0.0-27.3]
Part B2 No prior third-generation EGFR-TKI, T790M negative; (600 mg ^[1] ; n=51)	9.0 [5.5, 11.9]	10.1 [0.0-27.5]
Part B3 No prior third-generation EGFR-TKI, T790M positive; (600 mg ^[1] ; n=18)	11.0 [4.0, NR]	14.7 [1.2-29.3]


Progression data had a maturity of 62%.

Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. Circles indicate censored observations.



Progression data had a maturity of 40%.

Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST assessment. Circles indicate censored observations.



PFS= Progression Free Survival; EGFR = Epidermal Growth Factor Receptor; TKI = Tyrosine Kinase Inhibitor; [1] Most patients were enrolled to Part B1, B2, B3 on 600 mg savolitinib, prior to weight-based dosing implementation, but following a protocol amendment in response to a safety signal of hypersensitivity, the final 21 patients enrolled in Part B were dosed with savolitinib by body weight as follows: patients who weighed \leq 55 kg (n=8) received 300 mg daily and those weighing >55 kg (n=13) received 600 mg daily. 39

TATTON B & D data – AEs & tolerability Tagrisso[®] + savolitinib in EGFR TKI refractory NSCLC



Event, n (%)	All Part B (n=138)	Part D (n=42)
Any AE	135 (98)	39 (93)
Any AE possibly related to savolitinib	115 (83)	25 (60)
AE grade \geq 3	79 (57)	16 (38)
AE possibly causally related to study treatment leading to discontinuation of:		
Savolitinib	38 (28)	9 (21)
Osimertinib	14 (10)	2 (5)
Any AE leading to death	6 (4)	2 (5)
Any SAE	62 (45)	11 (26)

Part D data are preliminary, therefore, for osimertinib, the mean actual treatment exposure was 8.5 months for Parts B and D, respectively, and 7.1 months vs 4.9 months for savolitinib, for Parts B and D, respectively Han J. et al, "TATTON expansion cohorts: a Phase Ib study of osimertinib plus savolitinib in patients with EGFR-mutant, MET-amplified NSCLC following disease progression on a prior EGFR-TKI", #LBA, ESMO Asia, Singapore, November 23, 2019;

TATTON B & D data – AEs & SAEs Most common $AEs^{[1]}$ independent of causality & SAEs (\geq 3%)^[2]




	All Part B (n=138) Part D (n=42)		Δ Γ * p (0/)	All Part B	s (n=138)	Part D	(n=42)		
AE*, n (%)	All grades	Grade \geq 3	All grades	Grade \geq 3	AE*, n (%)	All grades	Grade \geq 3	All grades	Grade \geq 3
Nausea	67 (49%)	4 (3%)	13 (31%)	0	Rash	26 (19%)	3 (2%)	8 (19%)	0
Fatigue	48 (35)	6 (4)	4 (10)	0	Stomatitis	26 (19)	0	4 (10)	0
Decreased	47 (24)	Γ (Λ)	((1A))	1 (2)	Constipation	26 (19)	0	3 (7)	0
appetite	47 (34)	5 (4)	6 (14)	1 (2)	Pruritus	24 (17)	1(1)	5 (12)	0
Vomiting	46 (33)	6 (4)	5 (12)	0	Headache	23 (17)	0	3 (7)	0
Oedema		2 (2)	0(10)	0	Myalgia	22 (16)	3 (2)	6 (14)	1 (2)
peripheral	44 (32)	3 (2)	8 (19)	0	Cough	22 (16)	0	4 (10)	1 (2)
Diarrhoea	39 (28)	4 (3)	8 (19)	2 (5)	AST increased	21 (15)	9 (7)	2 (5)	0
Paronychia	30 (22)	3 (2)	7 (17)	0	Pneumonia	15 (11)	7 (5)	7 (17)	5 (12)
Pyrexia	29 (21)	1 (1)	6 (14)	0					

SAE**, n (%)	All Part B (n=138)	Part D (n=42)
Pneumonia	5 (4%)	4 (10%)
Anaphylactic reaction	6 (4)	1 (2)
Pneumothorax	6 (4)	1 (2)
Pyrexia [#]	5 (4)	0
Dyspnoea	5 (4)	0
Drug hypersensitivity	4 (3)	1 (2)
Diarrhoea	4 (3)	1 (2)
Back pain	4 (3)	0
Pulmonary embolism	3 (2)	2 (5)

[1] \geq 15% in either Part B or Part D for all grades; [2] \geq 3% in either Part B or Part D for all grades. [#]The emergence of drug-related hypersensitivity AEs are characterised by events such as pyrexia; The emergence of hypersensitivity and anaphylaxis events led to a protocol amendment introducing a weight-based savolitinib dosing regimen (for the last group of patients enrolled in Part B) in parallel to the lower dose of savolitinib (300 mg) being tested (for all patients enrolled in Part D)


SAVANNAH Study Encouraging TATTON data – led to the initiation of SAVANNAH







Savolitinib + Imfinzi[®] combination



[1] KEYNOTE 427 (Cohort B) ASCO GU 2019 D. McDermott; CALYPSO (PRCC cohort) ASCO GU 2019 C. Suarez; Abstract 548 (244057) ASCO GU 2019 R.McKay; ORR = Objective Response Rate; DCR Disease Control Rate; mPFS = median Progression-Free Survival.





3 H1 2019 Financial Results, Cash & Guidance

H1 2019 Financial results R&D expense accelerated to \$74.5m in first 6 months



	2018	H1-18	H1-19	Growth	at CER [(Non-GAA)
GROUP REVENUES	214.1	102.2	102.2	-	+5%
Unconsolidated JV Revenues	491.5	271.7	276.9	+2%	+8%
SEGMENT NET INCOME/(LOSS) ^[1]					
INNOVATION PLATFORM	(102.4)	(52.9)	(63.8)	-21%	-29%
COMMERCIAL PLATFORM	41.4	26.9	27.7	+3%	+9%
Prescription Drugs Business	32.1	20.8	21.8	+5%	+11%
Consumer Health Business	9.3	6.1	5.9	-4%	+2%
Chi-Med Group Costs	(13.8)	(6.7)	(9.3)	-39%	-39%
GROUP NET LOSS ^[1]	(74.8)	(32.7)	((45.4))	-39%	-48%
EPS Attrib. to Ord. S-H (Basic) (US\$)	(0.11)	(0.05)	(0.07)		

[1] Net Income / (Loss) attributable to Chi-Med; [2] at CER = at Constant Exchange Rate, which is a non-GAAP financial measure used to present period-to-period comparisons without the

effects of currency movements by retranslating the current period's performance at the previous period's foreign currency exchange rates. Please refer to the slides titled "Non-GAAP Financial

Measures and Reconciliation" for more information and a reconciliation of these measures to the most comparable GAAP measure.

Gi Inne

On

Existi Bu

Cash position & 2019 Guidance \$384 million in available cash resources ^[1]



Cash Position (at end June 2019)

\$237 million cash / cash equiv. / Short term inv. ^[2]

\$147 million additional unutilized banking facilities [3]

\$64 million additional cash in JVs

\$0 million in bank borrowings



(US\$ millions)	2019 Guidance
Research & Development Expenses	(130) - (170)
Adj. (non-GAAP) Group Net Cash Flows ^[4]	(90) - (120)

Flexibility on timing of future financing activity:

- Sufficient resources to advance pipeline through multiple major value inflection points;
- > Non-dilutive finance from non-core CP divest. [5]

[1] Including cash, cash equivalents, short-term investments & unutilized banking facilities; [2] Short-term investments: deposits over 3 months; [3] From Bank of America Merrill Lynch, Deutsche Bank, Hong Kong Shanghai Banking Corporation; [4] Adjusted (non-GAAP) Group net cash flows excluding financing activities. Please refer to the slides titled "Use of Non-GAAP Measures and Reconciliation" for more information and a reconciliation of these measures to the most comparable GAAP measure; [5] Potential for non-dilutive finance derived from the disposal of certain non-core Commercial Platform assets.





What is next from discovery? Differentiated assets against multiple targets



Priming & activations aOX40 4-1BB


Antigen release

- MET (savolitinib)
- EGFR (epitinib/theliatinib)
- Syk (HMPL-523)
- PI3Kδ (HMPL-689)
- FGFR (HMPL-453)

• IDH 1/2 (HMPL-306)



RIP1K



<u>Anti-angiogenesis</u>

- VEGFR (fruquintinib)
- VEGFR/FGFR (surufatinib)
- FGFR (HMPL-453)

Negative regulators

- Treg (HMPL-689)
- CSF-1R (surufatinib)
- IDOi
- AhRi
- TIM3
- **TCBs**

Pre-clinical - small moleculePre-clinical - antibody

Creating highest-quality range of assets against novel targets for use in combos


Note: Adapted from Chen DS et al. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, Volume 39, Issue 1, 1 - 10.; CAN = Candidate Nomination (clear for regulatory tox).

CHI-MED

Objectives for existing assets 2019-2021



- NDA submission for savolitinib combo with Tagrisso®
- Expand savo. Exon14 deletion development global
- 2 compounds to enter registration studies in 2020, surufatinib & fruquintinib
- **Proof-of-concept achieved** on both Syk & PI3Kδ compounds



- Establish Elunate[®] as best-in-class VEGFR TKI in >\$5bn market by 2026^[1]
- 2 new NDAs in '19/'20, suru. ep-NET & savo. Exon14d NSCLC
- 2 more compounds into registration trials in 2020, Syk & PI3Kδ
- Expanded life cycle development on all assets, incl. PD-1 combos

Existing China Business

- Cash generative China Commercial Platform
- Platform for future innovative drug launches

Chi-Med in short



19-year track record of achievement & discipline

- In-house discovery excellence world-class scientific talent & strategy discovery platform that has created all clinical assets internally;
- **Proven development** the first China company to bring home-grown asset to market^[1];
- **Commercial excellence** deep knowhow & infrastructure in China profitable.

Risk-balanced – non-binary biotech

- **Multiple shots-on-goal** 9 novel drug candidates^[2] two proven through pivotal studies^[3];
- World-class partnerships AstraZeneca & Eli Lilly as well as wholly-owned assets.

Ambition

• Building a global science-focused biopharma company from an established base in China.





HUTCHISON CHINA MEDITECH

Thank you







Strategies - Global Innovation

Pushing the envelope on our most valuable assets

One of China's largest & most established discovery platforms in oncology





Global step-change innovation

• Aiming for multiple potential first-in-class assets



Kinase selectivity – enable combos

• Limit off-target toxicity & address TKI resistance



Discovery of broad range of assets against novel targets






Attack cancer from multiple angles at same time

Immune Desert Insufficient T cell response

- Chemotherapies
- Vaccines
- CAR-T (pro-inflammatory strategies)
- TCB's

Antigen Release

- Aberrant genetic drivers
- Targeted therapies (small molecule & antibody)



Excluded Infiltrate Inadequate T cell homing

- Anti-angiogenics
- Stromal targets
- Chemokines
- Vaccines

Inflamed


Inactivated T cell response

- Immunotherapies (address negative regulators)
- Vaccines

Need combinations of potent, yet tolerable drugs against specific targets

Our advanced medicinal chemistry provides superior selectivity & safety profiles...






Savolitinib

∽1,000 times more selective to c-MET than next kinase (PAK3) ^[5]

> Screening at 1µM against 253 Kinases



Fruquintinib Capsules ~250 times more selective to VEGFR3 than next non-

VEGFR kinase (Ret) ^[6]

	Discont	inuations as %	Enrolled
Non-small cell lung cancer (NSCLC)	Due to AE	Withdrawn / Other	Total ^[1]
Monotherapy - Tagrisso® / savolitinib			
Tagrisso® (osimertinib)	6%	6%	13%
savolitinib 600mg QD PRCC (for reference only – not NSCLC) ^[2]	9%	5%	14%
Combination - Tagrisso® + savolitinib			
savolitinib 600mg QD + Tagrisso® [3]	29%	6%	35%
Approved treatments in NSCLC			
Zykadia® (ceritinib)	10%	10%	20%
Cyramza® (ramucirumab) + Taxotere ®	15%	21%	37%
Keytruda® (pembrolizumab) 2mg/kg	10%	26%	37%
Opdivo ® (nivolumab)	15%	4%	20%
Chemo doublet (platinum + pemetrexed)	11%	17%	27%
Taxotere® (docetaxel)	13%	22%	36%

3 rd -Line Metastatic CRC) Study nd China		CONCUR Study (China, HK, Taiwan) ^[4]		
Treatment arms	Elunate®	Placebo	Stivarga [®]	Placebo		
VEGFR on-target related AEs:						
Hypertension ≥G3	21.2%	2.2%	12.5%	8.3%		
Hand-Foot Syndrome (Palmar-plantar), ≥G3	10.8%	0.0%	17.0%	0.0%		
Off-target (i.e. non-VEGFR) related AEs:						
Hypophosphatemia, ≥G3	0.0%	0.0%	8.0%	0.0%		
Hypokalemia, ≥G3	0.7%	0.7%	6.3%	0.0%		
Rash/desquamation, ≥G3	0.0%	0.0%	4.4%	0.0%		
Lipase increase, ≥G3	0.0%	0.0%	6.3%	1.7%		
Hepatic function (Liver function) AEs:						
ALT increased, ≥G3	0.7%	1.5%	7.1%	3.3%		
AST increased, ≥G3	0.4%	0.7%	8.9%	0.0%		
Blood bilirubin increased, ≥G3	1.4%	1.5%	8.9%	8.3%		
Tolerability:						
AE Leading to dose interruption	35.3%	10.2%	68.8%	25.0%		

[1] Total discontinuations = Discontinuations NOT due to Disease Progression or Death; [2] September 2017 Journal of Clinical Oncology; [3] 2019 AACR # CT032, CT033; [4] Efficacy & safety of regorafenib monotherapy in Chinese patients with previously treated metastatic colorectal cancer: subgroup analysis of the CONCUR trial; R Xu; [5] W. Su, et al, 2014 American Association of Cancer Research; [6] Sun et al., Cancer Biology & Therapy 15:12, 1635--1645; December 2014.

Superior safety allows for combinations TKI + TKI combos to address acquired resistance






- MET amplification is the most common resistance mechanism for Tagrisso[®].
- Requires addition of MET inhibitor savolitinib – in combo with Tagrisso[®].


RESULTS: CANDIDATE ACQUIRED RESISTANCE MECHANISMS WITH OSIMERTINIB (n=91)*

- No evidence of acquired EGFR T790M
- The most common resistance mechanisms were *MET* amplification and EGFR C797S mutation • Other mechanisms included *HER2* amplification, *PIK3CA* and *RAS* mutations





- C481S or PLCγ are the most common resistance mechanisms for Imbruvica[®].
- Invalidating BTK inhibitor requires a possible Syk, PI3Kδ &/or BTK TKIs.



5 assets in global development ...US/EU clinical & regulatory team fully operational



Program	Treatment	Indication	Target patient	Study name	Sites	Dose finding / safety run-in	Proof-of-concept	Registration
	Savolitinib + Tagrisso®	NSCLC	2L/3L EGFRm; Tagrisso [®] ref.; MET+	SAVANNAH	Global	Oxnard/Ahn – DF/SMC		
	Savolitinib + Tagrisso®	NSCLC	2L EGFRm; EGFR TKI ref.; MET+	TATTON	Global	Oxnard – Dana Farber		TATTON B/D Data
	Savolitinib + Imfinzi® (PD-L1)	Papillary RCC	All	CALYPSO	UK/Spain	Powles – Queen Mary's		ESMO Asia Nov 2019
Savolitinib	Savolitinib + Imfinzi® (PD-L1)	Clear cell RCC	VEGFR TKI refractory	CALYPSO	UK/Spain	Powles – Queen Mary's		
MET	Savolitinib	Gastric cancer	MET+	VIKTORY	S Korea	Lee – Samsung Med. Ctr		Prelim. PoC at ASCO GU Feb 2019
	Savolitinib + Taxotere®	Gastric cancer	MET+	VIKTORY	S Korea	Lee – Samsung Med. Ctr [1]		ASCO BO FED 2017
	Savolitinib + Taxotere®	Gastric cancer	MET over-expression	VIKTORY	S Korea	Lee – Samsung Med. Ctr [1]		Prelim, PoC
	Savolitinib	Prostate cancer	MET+	CCTG I234B	Canada	Kolinsky/Muk'jee/Ong/Chi		H2 2019
	Fruenistisib		21/41, Ctiusres [®] (Longure [®] rof (intol		uc	Fre /Deceri AD and [2]		
Fruquintinib VEGFR 1/2/3		Colorectal cancer	3L/4L; Stivarga [®] /Lonsurf [®] ref./intol.		US	Eng /Desari – MD And. [2]		Planning US/EU registr.
VEGER 1/2/3	Fruquintinib + Tyvyt [®] (PD-1)	Solid tumors			US	In planning		study based on FRESCO/US Ph.Ib
Surufatinib	Surufatinib	Pancreatic NET	2L; Sutent [®] /Afinitor [®] refractory		US	Dasari/Yao – MD Anderson		
VEGFR 1/2/3; FGFR1; CSF-1R	Surufatinib + Tuoyi [®] (PD-1)	Solid tumors				In planning		Planning US/EU registr. study based on China
								Ph.II/US Ph.Ib
HMPL-523	HMPL-523	Indolent NHL			Australia			
Syk	HMPL-523	Indolent NHL			US	Fowler – MD Anderson		Global Ph.I/PoC data-set
		Hoolthuyoluptoor						110W at 11 7 140
HMPL-689	HMPL-689	Healthy volunteers			Australia			Data-set now emerging
ΡΙ3Κδ	HMPL-689	Indolent NHL			US	Ghosh/Cohen-Levine/Emory		in China Ph.I (n ~40)

[1] Further patient enrollment directed to savolitinib monotherapy arm due to the high efficacy observed; [2] in U.S., in E.U. Tabernero - Vall d'Hebron & Sobrero - Genova.

Note: MET = mesenchymal epithelial transition receptor, VEGFR = vascular endothelial growth factor receptor, EGFRm = epidermal growth factor receptor mutation, FGFR1 = fibroblast growth factor receptor 1, CSF-1R = colony stimulating factor-1 receptor, Syk = spleen tyrosine kinase, PI3Kδ = Phosphatidylinositol-3-Kinase delta, NSCLC = non-small cell lung cancer, RCC = renal cell carcinoma, NHL = Non-Hodgkin's Lymphoma, AACR = American Association of Cancer Research annual meeting, ASCO GU = American Society of Clinical Oncology Genitourinary Cancer Symposium, PoC = Proof of Concept.

59

Global Innovation Main targets for 2019-2021

Aim for Savolitinib / Tagrisso® combo NDA submission



- US/EU C&R operation set up in Florham Park, NJ
- Accelerate development of 4 un-partnered global assets
 - Fruq (ex-China) & suru registration studies & exploration of combos with PD-1s;
- *Syk & PI3K*δ registration studies & exploration of combos with other TKIs















Strategies – China Oncology *Next-gen oncology drugs to meet major needs in China*

China oncology - ~24% of world's cancer patients^[1] (MED)



Industry's attention turning to unmet medical need in China oncology

- Regulatory reforms in China addressing low SoC [2]
- Major investment inflow



Chi-Med is a first mover

- Elunate[®] launch in 3L mCRC; First ever in China^[3]
- Deep pipeline 8 clinical drug candidates with 5 registration studies underway/set to start in China




• National Drug Reimbursement; Medical coverage




China now world's 2nd largest pharma market ...investment, approvals & access all accelerating rapidly







PRC Healthcare VC/PE Funds^[2]








Number of Priority Review NDAs^[3]



Medical Insurance Coverage ^[1]



Improved Access since 2017


- 128 western drugs added to NRDL;
- Further 17 oncology drugs added to NRDL in Oct 2018 (15 in Jul 2017);
- Essential drug list expanded from 520 to 685 molecules. Including oncology.

Source: McKinsey

[1] Urban Basic Medical Care Insurance (for both employees & residents) - total persons covered at year-end. National Bureau of Statistics (2017); includes rural residents from 2017 and beyond; [2] Funds raised; [3] NDA = New Drug Application. Note: CAGR = Compound annual growth rate.

Cancer is a major unmet need in China ... investments in launches/access starting to have an impact





8 assets in China development ... frug launched – savo/suru NDAs & Syk/PI3K δ PoC ahead



Program	Treatment	Indication	Target patient	Study name	Sites	Dose find / safety run-in	Proof-of-concept	Registration	Enrolled
e	Savolitinib	NSCLC	MET Exon 14 deletion		China	Lu Shun – SH Chest Hosp.			n >70
Savolitinib MET	Savolitinib + Iressa®	NSCLC	2L EGFRm; Iressa [®] ref.; MET+		China	Wu Yilong – GD General			
	Savolitinib	Gastric cancer	MET+		China	Shen Lin – BJ Univ. Tumor			Launched
	Fruquintinib	Colorectal cancer	≥3L; chemotherapy refractory	FRESCO	China	Li Jin – Fudan Univ.		-	Nov 2018
	Fruquintinib + Taxol®	Gastric cancer	2L	FRUTIGA	China	Xu Ruihua – Sun Yat Sen			Interim OK
Fruquintinib	Fruquintinib	NSCLC	3L; chemotherapy refractory	FALUCA	China	Lu Shun – SH Chest Hosp.			April 2019
VEGFR 1/2/3	Fruquintinib + Iressa®	NSCLC	1L EGFRM		China	Lu Shun – SH Chest Hosp.			ESMO Asia
	Fruquintinib + Tyvyt® (PD-1)	Solid tumors			China	Bai Yuxian - Harbin Med. U.			Nov 2019
	Fruquintinib + genolimzumab (PD-1)	Solid tumors			China	Li Jin – Fudan Univ.			Interim
	Surufatinib	Pancreatic NET	All	SANET-p	China	Xu Jianming – #5 Med. Ctr.			H1 2020
	Surufatinib	Non-Pancreatic NET	All	SANET-ep	China	Xu Jianming – #5 Med. Ctr.			
VEGFR 1/2/3; FGFR1; CSF-1R	Surufatinib	Biliary Tract cancer	2L; chemotherapy refractory		China	Xu Jianming - #5 Med. Ctr.			NDA accepted
	Surufatinib + Tuoyi [®] (PD-1)	Solid tumors			China	Shen Lin – BJ Univ. Tmr.			Nov 2019
	HMPL-523 + azacitidine	Acute Myeloid Leuke.	1L		China	Wang/Qi - CN Hem. Hosp.		Planning	g China Ph.II/III
HMPL-523	HMPL-523	B-cell malignancies	All		China	Multiple leads by sub-types		in seve	ral iNHL types
Syk	HMPL-523	ITP	All		China	Yang – CN Hem. Hosp.		Ph.Ib da	ta now n >140
HMPL-689	HMPL-689	Indolent NHL			China	Cao/Zhou – Fudan/ Tongji		Data-se	t emerging in
ΡΙ3Κδ									Ph.I (n ∽40)
Epitinib	Epitinib	NSCLC	EGFRm with brain metastasis		China	Wu Yilong – GD General			
	Epitinib	Glioblastoma	EGFR gene amplified		China	Ying Mao – SH Huashan			
Theliatinib EGFR wt	Theliatinib	Esophageal cancer	EGFR over-expression		China	Shen Lin – BJ Univ. Tumor [1]			
HMPL-453 FGFR 1/2/3	HMPL-453	Solid tumors			China	Xu Ruihua - SYS			

[1] Discontinued. ITP = immune thrombocytopenic purpura; PoC= proof of concept.

China Oncology Main targets for 2019-2021



Sestablish Elunate[®] as the best-in-class VEGFR TKI in China market

- Work with Lilly to maximize penetration & sales performance;
- Aggressively expand PD-1 combination collaborations & broader LCI program

C Launch our un-partnered oncology drugs

- Target surufatinib NDA in neuroendocrine tumors;
- Expand Oncology Commercial Organization in China

Savolitinib NDA in MET Exon 14 NSCLC

Progress development pipeline

- Syk & PI3Kδ into registration studies & aim to establish PoC for epitinib, theliatinib & FGFR;
- Aim for further novel drug candidates into early development each year



A1c Strategies - Existing China Business Cash generation & China commercial know-how / infrastructure

Existing China business





Chi-Med spent 17 years building **China commercial presence**

- Valuable know-how in operating within the complex medical system in China
- Clear operating synergies with our novel oncology assets
- China operations/JVs have generated >\$210 million dividends since inception



China pharma industry grew at circa. 10% CAGR over last 15 years

Aging population; rapid urbanization; economic development

Chi-Med's Commercial Platform in China Integrated platform built from ground up



2 National House-Hold Name Brands



Major Commercial & Production Scale

>2,400 RX & ~900 OTC sales people in over 330 ^[1] cities & towns in China.

Drugs in ~24,400 hospitals detailing ~88,400 doctors.

Sold ~4.8 billion doses of medicine in 2018.

Leadership Market Shares

Market leader in the subcategories/markets in which we compete ^[2]:

SXBX pill: ^{[3][4]}	∽17%
Rx Cardiovascular TCM	
Banlangen: ^[5]	∽ 54%
OTC Anti-viral /flu TCM	
FFDS tablet: ^[6]	∽ <mark>38%</mark>
OTC Angina TCM	

JVs with 3 Major China Pharmas










[1] 330 cities & towns covered by Prescription Drug Business and 600 cities & towns including OTC business; [2] Frost & Sullivan 2018 market share data; [3] China coronary heart disease oral Chinese patented drugs market share; [4] She Xiang Bao Xin Pill ("SXBX pill") - Rx Coronary artery disease; [5] Banlangen Granules ("Banlangen") - OTC Antiviral; [6] Fu Fang Dan Shen tablets ("FFDS") - OTC Angina.


Established Rx Commercial Platform in Mainland China... Chi-Med management run all day-to-day operations




Chi-Med's Commercial Platform in China Proven track record, ~\$300 million in net income since inception



Revenues (Non-GAAP) [1][2]



Net Income/(Loss) attrib. to Chi-Med



[1] 2003-2006 incl. disco. operation; [2] Excluding Guanbao (from 2011 until divested in Sep 2017); [3] Based on aggregate Non-GAAP net income / (loss) of consolidated subsidiaries and non-consolidated joint ventures of Commercial Platform, please see appendix "Non-GAAP Financial Measures and Reconciliation"; [4] at Constant Exchange Rate (at CER), which is a non-GAAP financial measure used to present period-to-period comparisons without the effects of currency movements by retranslating the current period's performance at the previous period's foreign currency exchange rates. Please refer to the slide titled "Non-GAAP Financial Measures and Reconciliation" for more information and a reconciliation of these measures to the most comparable GAAP measure.

Existing China Business Plans for 2019-2021





• Focus on proprietary prescription drug products

🕀 Build out synergies with China Oncology Organization

Strategically evaluate potential for M&A









Product Candidate Details Further details on each drug candidate







Savolitinib (AZD6094) Potential first-in-class selective MET inhibitor


Savolitinib (AZD6094)



Potential first-in-class selective MET inhibitor

LIVIE

- 1. Strong potential to become first selective MET inhibitor approved in certain indications.
 - Clear clinical efficacy observed in non-small cell lung ("NSCLC"), kidney, gastric and colorectal cancers.
 - Partnered with AstraZeneca key comp. advantages in NSCLC (Tagrisso® combo) & biomarker testing.
- 3. Savolitinib design eliminates renal toxicity first
 generation of selective MET inhibitors encountered ~900 patients involved in clinical studies to date.



2-quinolinone metabolite in humans in 1st-gen MET compounds has dramatically reduced solubility and appeared to crystallize in the kidney resulting in obstructive toxicity.

2. MET is aberrant in many tumor settings. [7]

		New Cases (2018)			
Indication	Amplification	Mutation	Over- Expression	Global	China
Gastric	10%	1%	41%	1,033,700	442,300
Non-small Cell Lung Cancer	4%/16%/30% [1]	2% [2]	39%	1,779,800	737,400
Head & Neck	17-39%	11% [3]	46% [4]	887,700	137,000
Colorectal	10%	3%	65%	1,801,000	426,700
Papillary Renal Cell Carcinoma	64%	70-100% [5]	55%	45,400	3,700
Clear Cell Renal Cell Carcinoma	54%	NA	35%	281,300	57,500
Esophagus	8%	NA	92%	572,000	271,600
Prostate	NA	NA	54/83% [6]	1,276,100	99,300

4. AstraZeneca collaboration & 2016 amendment.

- \$20m received upfront (Dec 2011);
- \$120m in development/approvals milestones (\$25m received as of June 2019);
- Several hundred million in commercial milestones;
- Development costs: AZ pay 100% ex-China (excl. \$50m by Chi-Med) & 75% development cost in China (Chi-Med 25%);
- From 9% up to 18% tiered royalty ex-China ^[8] & 30% flat rate China royalty on all product revenues.

[1] MET amplification in non-small cell lung cancer patients occurs in approximately 4% of patients not previously exposed to systemic therapies and in approximately 16% to 30% of patients with acquired resistance to EGFR inhibitors; [2] MET Exon 14 skipping mutation only; [3] Oropharynx squamous cell cancer only; [4] Head and neck squamous cell cancer only; [5] Type 1 papillary renal cell carcinoma only; [6] MET expression is increased with progression of prostate cancer, which is 54% of lymph node metastases and 83% of bone metastases; [7] Company estimates considering Frost & sulfiven data, National Central Cancer Registry of China and publicly available epidemiology data; [8] Base royalty of 9%-13%. Additional 5% royalty subject to approval in the papillary renal cell carcinoma (PRCC) indication, for a total of 14%-18% tiered royalty. After total agregate sales of savolitinib have reached \$5bn, the royalty will step down over a two-year period, to an ongoing royalty rate of 10.5% to 14.5%.

Savolitinib – MET Exon 14 deletion NSCLC China's lead MET inhibitor




1. Competitive landscape outside China:


· · · ·	•		Treatment Line	N	BICR ^[1] ORR	95% CI
Capmatinib (Novartis/ Incyte) selective MET		ASCO 2019 #9004	2/ <u>3L</u>	69	40.6% (28/69)	28.9%, 53.1%
	SCIECTIVE MET	ASCO 2019 #9004	1L	28	67.9% (19/28)	47.6%, 84.1%
Tepotinib (Merck Serono)	selective MET	ASCO 2019 #9005	39% 1L, 61% ≥2L	51	45.1% (23/51)	31.1%, 59.7%
Xalkori®	multi kinaca	WCLC 2018 #13453	38% 1L	65	32.3% (21/65) ^[2]	21%, 45% ^[2]
(Pfizer)	multi-kinase	WCLC 2018 #12937	Median 1L (1L-4L)	25	40.0% (10/25)	21%, 61%

2. Xalkori[®] a multi-kinase TKI – selective MET inhibitors reporting better response – superior selectivity.

	Savolitinib IC ₅₀	Xalkori® IC ₅₀	Savolitinib vs. Xalkori®
EBC1 Viability	2nM	19nM	10x
EBC1 pMET	1	39	40x
293T MET (wild type)	7	79	11x
293T MET (Ex14del)	9	140	16x



[1] BICR = blinded independent central review; [2] Investigator reviewed data (not BICR); [3] Paik, P.K., et al., Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov, 2015. 5(8): p. 842-9.



2. Potential in EGFR-TKI resistant NSCLC:

✓ Must shut down both EGFRm & MET signaling pathways;

Prolonged tumor growth suppression by combining

savolitinib with Tagrisso® (osimertinib - EGFR/T790M) or

Savolitinib – EGFR-TKI resistant NSCLC Very strong preclinical rationale for combination w/ EGFR-TKIs

1. 2nd Line NSCLC is a fast and attractive indication

for savolitinib to go after. Also important unmet

medical need and potential **Breakthrough Therapy**

area.



76

MET+ / T790M unk.

(n = 5)

Savolitinib – 2L NSCLC^[1] combo w/ IRESSA[®] Encouraging in MET+ / T790M-, next step under discussion

MET+ (T790M-)

(n = 23)

Savo / Iressa[®] combo in 1st gen. EGFRm-TKI refractory patients^[2]...outstanding response in MET+ / T790M-

Confirmed response	2 (9%)	12 (52%)	2 (40%)
Stable disease≥ 6 weeks	9 (39%)	7 (30%)	2 (40%)
Progressive disease / death	7 (30%)	3 (13%)	0
Not Evaluable	5 (22%)	1 (4%)	1 (20%)
MET status all centrally confirmed.			

MET+/T790M+


(n = 23)

WCLC 2017

...vs. TATTON B data (savo / Tagrisso[®] combo)^[3]


	MET+ / T790M+ (n = 11) WCLC 2017 ^[2]	MET+ <i>(T790M-)</i> (n = 46) AACR 2019 ^[3]				
Confirmed response	6 (55%)	24 (52%)				
Stable disease \geq 6 weeks	NA (43% central confirm.)	16 (35%)				
Progressive disease / death	NA (0 central confirm.)	3 (7%)				
Not Evaluable	NA (0 central confirm.)	3 (7%)				
MET status locally or centrally confirmed.						







Savolitinib – 2L/3L NSCLC^[1] – TAGRISSO[™] resistant MET+ driven resistance in ~30% of patients



3 out of 3 MET+ patients responded to savo/Tagrisso[®] combo.





LUL Mass Pre-Treatment 6 wks. on savo/Tag. Treatment

Pt	EGFR mutation	# Prior Therapies	Prior 3 rd gen TKI	TISSUE (NGS, FISH)	PLASMA ctDNA (NGS)
1	L858R	1		<i>MET</i> amp, T790 WT	<i>MET</i> amp, T790M ND
2	Del19	1		-	T790M ND
3	Del19	2	Y	-	T790M ND
4	L858R (de novo T790M)	2	Y	<i>MET</i> amp, <i>EGFR</i> amp T790M (germline)	-
5	L858R	3	Y	T790wt, <i>EGFR</i> amp	T790M ND
6	L858R	4	Y	T790 WT	T790M ND
7	Del19	3	Y	-	T790M ND
8*	Del19	3		T790M/C797S	T790M/C797S
9	L858R	4	Y	T790 WT	-
10	Del19	3	Y	-	<i>PIK3CA</i> E545K, <i>PIK3CA</i> amp, T790M NI
11	Del19	2	Y	<i>MET</i> amp, <i>EGFR</i> amp, T790 WT	T790M ND
12	Del19	2	Y	-	T790M/C797S
13	Del19	9		T790 WT	-
7	Del19	2	Y	T790 WT	T790M ND
د	Del19	1		T790 WT	FGFR1 D60N, FGFR1 amp, T790M ND
16	L858R	2		<i>MET</i> amp, T790 WT	MET, EGFR amp, T790M ND
17	L858R	3	Y	T790 WT	T790M ND
18	Del19 (de novo T790M)	3		SCLC, T790 WT	T790M ND, <i>EGFR</i> amp
19	Del19	3	Y	T790 WT	T790M/C797S, <i>MET</i> amp, <i>EGFR</i> amp
20	L858R	2		<i>MET</i> amp, <i>EGFR</i> amp, T790 WT	-
21	L858R	3		-	T790M/C797S, <i>EGFR</i> amp
22*	L858R	1		MET amp, T790 WT	-
23	Del19	4	Y	-	T790M/C797S



Safety & tolerability

Tagrisso[®] & savo both highly selective/tolerable monotherapies (MED




	Efficacy				ficacy	Discontinuations as % Enrolled		
US FDA Approval	Treatment	Disease setting	n	ORR	Median PFS (mo.)	Due to AE	Withdrawn / Other	Total [5]
Monot	herapy – Tagrisso®/ savolitini	b						
30-Mar-17	Tagrisso® (osimertinib)	2L EGFRi-refractory T790M+ NSCLC (AURA3)	279	71%	10.1	6%	6%	13%
	savolitinib 600mg QD monotherapy [3]	All-lines Papillary RCC FOR REFERENCE ONLY NOT NSCLC	109 [1]	18%	6.2	9%	5%	14%
Combi	nation – Tagrisso® + savolitini	b						
	savolitinib 600mg QD + Iressa® (gefitinib) [2]	≥ 2L EGFRm+ MET+ T790M- NSCLC after 1 st -gen EGFR TKI (expansion)	51	52%	ND	20%	14%	33%
	savolitinib 600mg QD + Tagrisso® [3]	≥ 2L EGFRm+ MET+ T790M-/+ NSCLC after 1 st -gen EGFR TKI (TATTON B2)	51	69%	9.0	28%	ND	ND
	savolitinib 300mg QD + Tagrisso® [3]	≥2L EGFRm+ MET+ T790M-/+ NSCLC after 1 st -gen EGFR TKI (TATTON D)	42	68%	9.1	21%	ND	ND
	savolitinib 600mg QD + Tagrisso® [4]	≥ 3L EGFRm+ MET+ NSCLC after 3 rd -gen EGFR TKI (TATTON B1)	69	36%	5.4	28%	ND	ND
Approv	ed treatments in NSCLC							
29-Apr-14	Zykadia® (ceritinib)	2L ALK+ NSCLC after Xalkori (single arm)	163	56%	6.9	10%	10%	20%
12-Dec-14	Cyramza® (ramucirumab) + Taxotere ®	2L NSCLC after plat-chemo	624	23%	4.5	15%	21%	37%
24-0ct-16	Keytruda® (pembrolizumab) 2mg/kg	2L PD-L1+ (TPS≥1%) NSCLC after plat-chemo (KEYNOTE-010)	345	18%	3.9	10%	26%	37%
2-0ct-15	Keytruda® (pembrolizumab) 10mg/kg	2L PD-L1+ (TPS≥1%) NSCLC after plat-chemo (KEYNOTE-010)	346	18%	4.0	9%	27%	36%
9-0ct-15	Opdivo® (nivolumab)	2L NSCLC after plat-chemo	292	19%	2.3	15%	4%	20%
4-Mar-15	Opdivo ® (nivolumab)	2L squ. NSCLC after plat-chemo	135	20%	3.5	12%	8%	20%
2008	Chemo doublet (platinum + pemetrexed)	2L NSCLC (AURA3)	136	31%	4.4	11%	17%	27%
1999	Taxotere® (docetaxel)	2L NSCLC <i>(REVEL; KEYNOTE-010; Opdivo x2 aggregate total)</i>	1,391	12%	3.5	13%	22%	36%

Tagrisso® + savo combo tolerable even in late-stage ≥3L patients

[1] PRCC Phase II - Efficacy data from MET+ patients (n=44), discontinuation data from late 2017 data cut-off; Tolerability data from all patients (n=109); [2] WCLC 2017 #8995; [3] ESMO Asia 2019 LBA#2; AE data are pooled for cohort B patients; B had 48/51 efficacy evaluable patients; D had 34/36 efficacy evaluable patients; B1 had 59/69 efficacy evaluable patients; [4] Total discontinuations = Discontinuations NOT due to Disease Progression or Death; ND = Not Disclosed.


PRCC – unmet medical need Lower response rates to treatments






[1] Frost & Sullivan; [2] Frost & Sullivan, based on US incidence mix and global incidence rate in 2018; [3] NCCN Guideline for kidney cancer (Version 1.2020, June 7, 2019) preferred or category 1 options, RCC = renal cell carcinoma; [4] ORR = Objective Response Rate, mPFS = median Progression-Free Survival, mOS = median Overall Survival, NR = not reached; For approved subgroup of patients; [5] only approved for patients with intermediate or poor risk RCC.

Savolitinib – PRCC Phase II Clear efficacy & durable response in MET+ PRCC patients



2. MET- patients – no response to savo.




3. Disease Control Rate ("DCR") - big advantage in MET+ with DCR 73.2% vs. MET- 28.2%.^

Tumor responses in the overall treatment population and by MET status

RECIST response, n (%)	MET+ (n=44)	MET- (n=46)	MET unknown (n=19)	Total (n=109)
Partial Response [†]	8 (18.2%)*	0 (0.0%)	0 (0.0%)	8 (7.3%)
Stable Disease	22 (50.0%)	11 (23.9%)	5 (26.3%)	38 (34.9%)
Progressive Disease	11 (25.0%)	28 (60.9%)	9 (47.3%)	48 (44.0%)
Not Evaluable	3 (6.8%)	7 (15.2%)	5 (26.3%)	15 (13.8%)

* P=0.002 versus MET-independent subgroup (Fisher exact test). Responses assessed according to RECIST version 1.1.[†]Unconfirmed responses excluded. ^ Evaluable patients.

4. Median PFS - big advantage in MET+ patients.







8


Savolitinib – MET+ gastric cancer A major problem in east Asia – Japan, South Korea & China





2. MET+ disease is more aggressive [1]






[1] Catenacci, et al. "MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma." Cancer. 2017 Mar 15; 123(6): 1061–1070. doi: 10.1002/cncr.30437. [2] Lee, et al. "Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial." Cancer Discov. 2019 Jul 17. pii: CD-19-0442. doi: 10.1158/2159-8290.CD-19-0442. <5 patients in all other arms.

Savo potential in gastric cancer VIKTORY Phase II trial highly promising in MET+ gastric cancer












Fruquintinib – 24hr full target coverage





2. Selectivity and potency superior to competitors' drugs.


	Sutent [®] (sunitinib)	Nexavar® (sorafenib)	Stivarga® (regorafenib)	Tivozanib	Fruquintinib
Kinase profile	VEGFR1,2,3, PDGFRβ, FLT3, CSF-1R, c-Kit, Ret	RAF, VEGFR2, PDGFRβ Flt3, c-Kit, FGFR1	VEGFR1,2,3, Raf, Ret, PDGFR, c-Kit	VEGFR1,2,3, BRK, PDGFRα, PDGFRβ, c-Kit, Tie2, EphB2	VEGFR1,2,3
AUC at ED50/ED60 in mouse (ng/mL*hr)	2,058	25,473	na	1,640	898
MTD in human (mg/day)	50, qd	400, bid	160, qd	1.5, qd	4, qd; 6, 3wk/1wk
AUC, 0~24h at Steady state MTD (ng/mL*hr	592	47,780 x2 (D28)	58,270 (D21)	1,180 (D28)	5,000 <u>~6,000</u> (D28)
Efficacy in Phase I	22 patients PR: 4 (18%), DCR: 27%	45 patients ^[2] PR: 1 (2%), DCR: 58%	53 patients PR: 3 (6%), DCR: 66%	37 evaluable patients PR: 1 (3%), DCR: 51%	34 evaluable patients PR: 13 (38%), DCR: 82%

[1] Among small molecule tyrosine kinase inhibitors and to the best of Chi-Med's knowledge; [2] (\geq 100 mg bid); PR = Partial Response; DCR = Disease Control Rate.

Fruquintinib – 3L/4L colorectal cancer Develop in US/EU for rego/TAS-102 ref./intol. patients^[1]



Overall Survival (Primary Endpoint) FRESCO clearly succeeded in meeting the primary efficacy endpoint of OS



[1] ASCO = American Society of Clinical Oncology Annual Meeting.

86





Many "Firsts" for China biotech






上市会

ELUNATE Fruquintinib Capsules

Launched – Nov. 25, 2018







FALUCA – Third-line NSCLC Monotherapy Presented at WCLC 2019



FALUCA Phase III (enrolled Dec. 2015 to Feb. 2018)

- Met all secondary endpoints: mPFS; ORR; DCR; & DOR ^[1];
- Did not achieve primary endpoint of median OS, however:
 - Anti-tumor therapies after disease progression reduced OS diff.
 - Higher percentage of placebo pts received subsequent treatments.

Significant difference in subsequent anti-tumor treatments (ATT)

Chemotherapy: Fruq. **29.7%** vs. Placebo **53.8%**


Targeted therapies (VEGFi and/or EGFRi): Fruq. 20.9% vs. Placebo 31.2%

Tagrisso® & aniotinib just approved in 2017

Efficacy Endpoints (Intent-to-Treat)^[2]


	Fruq. (N=354)	Placebo (N=173)	p-value
mOS (mths)	8.94	10.38	0.841
mPFS (mths)	3.68	0.99	(0.001
ORR	13.8% (49)	0.6% (1)	(0.001
DCR	66.7% (236)	24.9% (43)	(0.001

PFS in ITT population



Good safety; most Grade ≥3 TEAEs target-related & clinically manageable.


נמועכנ-וכומנכט מ נ	נמועכנ-וכומנכט & כוווונמווע וומוומעכמטוכ.						
Patient (%)	Frug (N=354)	Pbo (N=173)					
TEAE \geq Grade 3	216 (61.2%)	47 (27.6%)					
Leading to discontinuation	37 (10.5%)	9 (5.3%)					
Leading to interruption	61 (17.3%)	7 (4.1%)					
Leading to dose reduction	85 (24.1%)	2 (1.2%)					
Hypertension	74 (21.0%)	5 (2.9%)					
Hand-foot syndrome	39 (11.0%)	0					



[1] mOS = median Overall Survival; mPFS = median Progression Free Survival; ORR = Objective Response Rate; DCR = Disease Control Rate; DoR = Duration of Response; HR = hazard ratio; 95% CI = 95% Confidence Interval; [2] Lu, et al. "A Randomized Phase III trial of Fruquintinib versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)," WCLC 2019 Abstract #MA14.05; [3] Lu, et al. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients with Advanced Non-Squamous Non–Small-Cell Lung Cancer (FALUCA)," WCLC 2019 Abstract #MA14.05; [3] Lu, et al. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology 36, no. 12 (April 20 2018) 1207-1217. Dol: 10.1200/JCO.2017.76.7145; [4] Li, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients with Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JMAA. 2018 Jun 26;319(24):2486-2496. doi: 10.1001/jama.2018.7855. *Post-hoc analysis

Fruquintinib – 1L NSCLC combo w/ IRESSA[®] gefitinib Two small molecule TKIs allow for better management of tox.






Data as of June 28, 2019.

2. Prelim. safety data: fruquintinib vs. other VEGFRis.

Adverse Events ("AEs")	Iressa® or Tarceva® FLAURA ^[5] N = 277, n (%)	Avastin® + Tarceva®[6] N = 75, n (%)	5mg Fruq. + Iressa® N = 26, n (%) ^[3]	4mg Fruq. + Iressa® N = 24, n (%) ^[3]
All AEs, any grade	273 (98%)	≥74 (≥99%)	26 (100%)	24 (100%)
All AEs, Grade ≥3	124 (45%)	68 (91%)	17 (65%)	11 (46%)
AEs leading to death	6 (2%)	0 (0%)	3 (12%)	0 (0%)
AEs to VEGFRi disc.	NA	31 (41%)	6 (23%)	4 (16%)
Grade ≥3 AEs:				
Liver function	33 (12%)	6 (8%)	13 (50%)	3 (13%)
Hypertension	NA	45 (60%)	1 (4%)	1 (4%)
Proteinuria	NA	6 (8%)	3 (12%)	1 (4%)
Rash	13 (5%)	19 (25%)	0 (0%)	1 (4%)
Decreased appetite	22 (8%)	1 (1%)	NA	NA

3. Combination of highly selective TKIs vs. mAbs: daily dose flexibility improves tolerability. This enables maintained drug exposure, leading to more durable response. ^[2,3]



[1] Best tumor response for efficacy evaluable patients (patients who had both baseline and post-baseline tumor assessments); ORR = objective response rate; [2] Four PRs not yet confirmed at the time of data cut-off date; mAb = Monoclonal Antibody;


[3] Lu, S., et al, "Phase II Study of Fruquintinib plus Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations", #4780 ESMO Asia, Singapore, November 23, 2019;

[4] Drug discontinuation due to Grade 3 proteinuria and Grade 3 QTC prolonged; [5] Ramalingam S. et al, "LBA2_PR Ösimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA", ESMO 2017 Congress, Madrid, Spain, September 9, 2017; [6] Seto, T., et al, "erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer harbouring EGFR mutations (J025567); an open-label, randomised, multicenter, phase 2 study", The Lancet 2014, 15 (11) 1236-1244.


Fruquintinib – Gastric combo with paclitaxel Phase III initiated Oct 2017 – Interim analysis early 2019



1. Dose proportional increase of fruquintinib AUC at steady state. Over 30% increase in paclitaxel drug exposure (mean AUC₀₋₈) following multiple dose fruquintinib.



2. ORR of 36% (10/28) & DCR of 68% in efficacy evaluable pts. Fruquintinib 4mg, ≥ 16 wk. PFS of 50% & ≥ 7 mo. OS of 50%.



Encouragingly low level of dose reduction/interruption.
 Actual mean administered dose in the first cycle was
 3.32mg/day for fruquintinib (83.0% planned dose) & 78.6
 mg/m2/week for paclitaxel (98.3% planned dose).


Characteristics (Unit)	Drug Expansion Stage (N=19) Fruquintinib 4 mg + paclitaxel 80 mg/m ²		
	Drug interruption	Drug reduction	
Dose modification with Fruquintinib N (%)	2 (10.5%)	2 (10.5%)	
Dose modification with Paclitaxel N (%)	5 (26.3%)	1 (5.3%)	

4. AE profile in-line with expectations. Neutropenia - a paclitaxel driven AE - with 57.9% Grade >3 AEs. Similar to 60% level seen in RAINBOW study of ramcirumab (VEGF mAb) combo with paclitaxel in second-line gastric cancer.


Drug related grade 3 or 4 AEs (NCI-CTCAE v 4.0) term	Dose Expansion Stage (N=19) Fruquintinib 4 mg + paclitaxel 80 mg/m²
Neutropenia	11 (57.9%)
Leukopenia	4 (21.0%)
Hypertension	2 (10.6%)
PLT decreased	1 (5.3%)
Anemia	1 (5.3%)
HFSR	1 (5.3%)
Mucositis oral	1 (5.3%)
Hepatic disorder	1 (5.3%)
Upper gastrointestinal hemorrhage	1 (5.3%)

Immunotherapy combinations... assets potentially (ideal TKI combo partners for immunotherapy





Multiple global immunotherapy combo deals...



[1] Sources: (i) B. Rini et al, for the for the KEYNOTE-426 Investigators, NEJM 2019 Feb 16. doi: 10.1056/NEJMoa1816714, Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma; (ii). D.F. McDermott et al, ASCO 2018 #4500, Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427; * ORR =38.2% for all PD-L1 expression combined positive scores (CPS) - ORR=50.0% for CPS≥1 pts, ORR=26.4% for CPS<1 pts.; [2] BTD = Breakthrough Therapy Designation.

Fruquintinib & surufatinib both unique VEGFR TKIspotentially ideal VEGFR combo partners for immunotherapy



TKI	1 st Generation		2	2 nd Generation		Next Generation		
Selectivity	Multiple targets		Relatively selective			Selective angio-immuno Highly selective kinase inhibitor		
Inhibitors	Sutent®	Nexavar®	Focus V [®]	Fotivda®	Lenvima®	Inlyta®	Fruquintinib	Surufatinib ^[1]
Status	Launched	Launched	Launched	Launched	Launched	Launched	Launched	Ph. IIIs ongoing
VEGFR1 (nM)	2	26	27	30	22	3	33	2
VEGFR2 (nM)	9	90	0.2	6.5	4	7	25	24
VEGFR3 (nM)	19	20	0.7	15	5	1	0.5	1
Phos-KDR (nM)	10	30	0.1-1	0.16	0.8	0.2	0.6	2
Other kinases (IC50 < 100nM)	PDGFR _α PDGFRβ c-Kit Flt3 Ret CSF-1R	Raf-1 b-raf Flt3 P38 C-Kit Ret	PDGFR _α PDGFR _β FGFR1-4 c-Kit	PDGFR _α PDGFR _β EphB2 c-Kit Tie2	PDGFR _α PDGFR _β FGFR1-4 Ret c-Kit	PDGFR _α PDGFR _β c-Kit	none	CSF-1R FGFR1 FLT3 TrkB
Patent Expiration					2021/10/19 (US7253286B2)	2025/04/29 (US6534524B1)	2029 (without extension)	2030 (without extension)

Fruquintinib is uniquely selective – unlike other TKIs with off-target toxicity
 Surufatinib inhibits TAM^[2] production – amplifying PD-1 induced immune response



Lilly amendment – Dec 2018 Secures long-term commercial potential



- Chi-Med will pay full cost of any future development in China. In return, Chi-Med gains:
- Section to operate in selecting & pursuing any future indications in China;
- Solution A series a series of the series of
- Section 2017 Freedom to collaborate with any third-party in clinical development; and
- Source Possible promotion rights in 30-40% of China for Elunate[®].^[2] Not expected before 2021, until then, Lilly responsible for all launch & commercialization costs in China. If we assume promotion rights, we will receive service fees, which we expect to be net income accretive.

	Original 2013 Agreement	Amendment (Dec 2018)
LCI ^[1] Development Costs – Paid by Lilly LCI Development Costs – Paid by Chi-Med	70% 30%	0%
LCI Regulatory Approval Milestones – Paid to Chi-Med [3]	12.5	20.0
Royalty Payments – Paid to Chi-Med ^[4]	15 - 20%	15 - 29%
Co-Promotion Rights in China (% of provinces) Co-Promotion Service Fees – paid to Chi-Med (% Net Sales)	0% 0%	30 - 40% Not disclosed

More control & higher long-term economics on bestin-class asset

[1] LCI = Life Cycle Indication; [2] upon achievement of a non-fruquintinib related Eli Lilly commercial action; [3] Lifecycle Indication - China - per LCI, up to 3 LCIs; [4] On Total Molecule Sales in China triggered upon launch of 1st LCI








Highly active TKI with unique angio-immuno activity


Surufatinib – China data ^{[1][2]} Broad spectrum NET efficacy incl. Sutent[®]/Afinitor[®] failure ptnts.



Phase III: Non-Pancreatic NET




Phase II: Pancreatic NET



Phase III: Safety - Well tolerated - Adverse Events manageable.

Adverse Events ("AEs")	Suru N=129 n (%)	Pbo N=68 n (%)	Grade≥3	Suru N=129 n (%)	Pbo N=68 n (%)
	11 (70)		Hypertension	47 (36.4)	9 (13.2)
Any TEAE	127 (98.4)	65 (95.6)	Proteinuria	25 (19.4)	0
Any Grade ≥3 AE	99 (76.7)	23 (33.8)	Diarrhea	2(1.6)	0
Any SAE	34 (26.4)	12 (17.6)	Bilirubin increased	3 (2.3)	0
Drug related AE leading	na to:		AST increased	5 (3.9)	2 (2.9)
-	-	15 (22.1)	Hypertriglyceridemia	3 (2.3)	0
dose interruption	62 (48.1)	15 (22.1)	ALT increased	4 (3.1)	0
dose reduction	62 (48.1)	5 (7.4)	Abdominal pain	1 (0.8)	0
drug withdrawal	23 (17.8)	4 (5.9)	Anemia	9 (7.0)	2 (2.9)

Phase II: Progression-Free Survival (PFS)



Progressive Disease on Prior TKI Prior Afinitor[®]

[1] ESMO 2019 LBA76; [2] ENETS = European Neuroendocrine Tumour Society oral presentation of SANET-1. Data cut-off as of Jan 20, 2017; NET = neuroendocrine tumors.

~170,000 NET patients in U.S.^{[1][2]}

U.S. NET treatment landscape - highly fragmented




		Somatostatin Based Therapies			Kinase Inhibitor Therapies		
	Sandostatin [®] LAR (octreotide)	Somatuline Depot [®] (lanreotide)	Lutathera® (¹⁷⁷ Lu-Dotatate)	Afinitor® (everolimus)	Sutent® (sunitinib)	Surufatinib (China NDA accepted)	
2018 Sales	\$1.6bn	\$1.0bn	\$0.17bn	\$1.6bn	\$1.0bn	· ·	
MOA ^[3]	Somatostatin analogue	Somatostatin analogue	Somatostatin receptor targeting radiotherapy	mTOR inhibition	Inhibits multiple receptor tyrosine kinases	VEGFR/FGFR1 & CSF-1R inhibition	
Admin.	Subcutaneous or intramuscular inj. (LAR)	Subcutaneous injection	Subcutaneous injections (radio- qualified physicians).	Oral tablet	Oral capsules	Oral capsules	
Shelf-life	3 years	2 years	72 hours	3 years	3 years	2+ years ^[5]	
Dosage	2 wks: Sando. inj. 0.1-0.6mg per day; then 2 months Sando. LAR 20mg per 4 wks.	120mg inj. every 4 wks.	7.4GBq (one ~25ml vial) inj. every 8 wks - 4 doses total.	10mg orally once daily.	37.5mg taken orally once daily.	300mg orally once daily.	
NET indication /s	LT treatment of severe diarrhea & flushing from meta. carcinoid tumors.	 <u>GEP-NETs</u>: unresectable, well or moderately diff., (locally adv. or meta) GEP-NETs to improve PFS. <u>Carcinoid Syndrome</u>: to reduce frequency of short-acting somatostatin rescue therapy. 	positive GEP-NETs.	 <u>pNET</u>: progressive pNET (unresectable, locally adv. or meta). <u>GI-NET or Lung NET</u>: progressive, well- diff., <i>non-functional</i> NET (unresectable, locally adv. or meta). Not for <i>functional</i> carcinoid tumors.^[4] 	 <u>pNET</u>: Progressive, well- differentiated pNETs (unresectable locally adv. or meta). 	 <u>Non-pNET</u>: SANET-ep study was in low- or intermediate- grade adv. non-pancreatic NET. <u>pNET</u>: Phase III ongoing. 	
Non-NET indication/s	• Acromegaly; watery diarrhea from VIPomas.	• Acromegaly.		• Adv. HR+ HER2-n breast cancer; adv. 2L RCC; renal angiomyolipoma and TSC.	• 2L GIST; adv. RCC; high risk of recurrent RCC.		

	Sandostatin® / Placebo	Somatuline Depot [®] / Placebo	Lutathera® + Sando. LAR / Sando. LAR	Afini Plac		Sutent®/ Placebo		ufatinib / Ilacebo
mPFS (mo.) primary EP	14.3 / 6.0	NR / 18.0	NR / 8.5	pNET 11.0 / 4.6	Lung & GI NET 11.0 / 3.9	pNET: 11.4 / 5.5	Ph II pNET 19.4	Ph III non-pNET 9.2 / <u>3.8</u>
HR	0.34	0.47	0.21	0.35	0.48	0.42	Ph III	0.33
(<i>p-value</i>)	0.000072	(0.001	(0.0001	(0.001	(0.001	(0.001	Ongoing	<0.0001
ORR	2% / 2%	NR	18%/3%	5% / 2%	2% / 1%	9% / 0%	17% (Ph II)	10.3%
DCR	69% / 40%	NR	95% / 76%	73%/51%	81% / 64%	72% / 60%	90% (Ph II)	87%
Pivotal Trial	PROMID	CLARINET	NETTER-1	RADIANT-3	RADIANT-4	A6181111	SANET-p	SANET-ep


[1] Dasari A, et al.: Trends in the Incidence, Prevalence, & Survival Outcomes in Patients With Neuroendocrine Tumors in the U.S.. JAMA Oncol. 2017;3(10):1335-1342; [2] www.cancer.net (patient information from ASCO) – NET is a subtype of neuroendocrine Tumors in the U.S.. JAMA Oncol. 2017;3(10):1335-1342; [2] www.cancer.net (patient information from ASCO) – NET is a subtype of neuroendocrine Tumors in the U.S.. JAMA Oncol. 2017;3(10):1335-1342; [2] www.cancer.net (patient information from ASCO) – NET is a subtype of neuroendocrine Tumors in the U.S.. JAMA Oncol. 2017;3(10):1335-1342; [2] www.cancer.net (patient information from ASCO) – NET is a subtype of neuroendocrine Tumors in China; [5] 2-year stability studies completed so far; mPFS = median progression-free survival; HR = Hazard Ratio; ORR = objective response rate; DCR = Disease control rate.

Surufatinib – China NET – Phase II *(ENETS 2017*^[1]) Tumor devascularization & central necrosis






Patient 2 Rectum NET G2 w/ multiple liver metastases











[1] Sources: AbbVie, Gilead Sciences, Pfizer and Roche 2018 annual reports; Rituxan[®] 2018 sales in oncology only; [2] Approved Drug = ®; All others are clinical candidates; [3] ASH = American Society of Hematology; [4] Chronic lymphocytic leukemia ("CLL") & small lymphocytic lymphoma ("SLL"); [5] Sharman et al, ASH Meetings 2015 & 2016; [6] CYP3A4, CYP2D6 and CYP 1A2.

Australia & China Phase I/Ib studies Extensive Ph.I dose escalation study now complete in Australia & China (total n=60); **Complete** Stage I: dose escalation "3 + 3" each dose cohort RP2D^[1] determined & large Ph. lb until disease • Australia: Relapsed/refractory Studied HMPL-523 N = 33progression, dose expansion study, total n=192, hematologic malignancy 100-1,000mg QD & death. 200-400mg BID in underway in 13 active sites in • China: Relapsed/refractory mature B intolerable N = 2713 dose cohorts lymphoma toxicity, etc. Australia & China; Phase I/Ib data set currently (> patients; Stage II: dose expansion ...Now enrolling US IND application cleared by FDA Relapsed or refractory, measurable & U.S./E.U. Phase I imminent; disease – multiple arms: until disease Aus Chronic lymphocytic leukemia progression, Plan to initiate China registration N = 40600mg QD Small lymphocytic lymphoma death, studies in 2019. China intolerable Mantle cell lymphoma N = 152toxicity, etc. • Follicular lymphoma Diffuse large B-cell lymphoma (PRC)

HMPL-523 (Syk) in hematological cancer Australia & China – large Ph.Ib expansion. US/EU Ph.I imminent


[1] RP2D = Recommended Phase II doses.

HMPL-689 – Phase I Australia & China ongoing Designed to be a best-in-class inhibitor of PI3K δ



1. PI3K δ now a proven target.

- PI3Kδ activation associated with allergy, inflammation & oncology.
- Evidence that PI3Kδ inhibitors effective in ibrutinib-resistant mutant population.



2. PI3K δ inhibitors being developed in a very broad range of indications.

Compound		Indication	Status	Issue
Zydelig® (idelalisib) PI3K&	Gilead	Chronic lymphocytic leukaemia, non-Hodgkin's lymphoma	Marketed	High incidence of liver toxicity seen with idelalisib (150mg bid)
AMG-319 PI3Kδ	Amgen	B-cell lymphoma, non-Hodgkin's lymphoma, T-cell lymphoma, chronic lymphocytic leukaemia	Phase I Trial	
Copiktra®	Verastem/	Relapsed or refractory chronic lymphocytic leukaemia / small lymphocytic lymphoma	Approved	Need to spare PI3Ky serious infection seen &
(duvelisib) PI3Kγ/δ		Relapsed or refractory follicular lymphoma	Approved ^[2]	associated with a boxed warning for 4 fatal and/or
		Peripheral T-cell lymphoma	Phase II enrolling	serious toxicities
Aliqopa® (copanlisib) PI3Kα/δ	Bayer	Relapsed follicular B-cell non-Hodgkin lymphoma	Approved ^[2]	Serious and fatal infections and AEs

3. HMPL-689 -- Important asset.

Designed to improve on existing $\text{PI3K}\delta$ inhibitors:

- Improved isoform selectivity (sparing PI3Kγ).
- Improved potency at whole blood level (>5x more potent than idelalisib) to cut compound related toxicity.
- Improved PK properties particularly efflux and drug/drug interaction due to CYP inhibition / induction, critical for combo therapy.

4. More potent / more selective than Zydelig[®], Copiktra[®] & Aliqopa[®].

Enzyme IC ₅₀ (nM)	HMPL-689	Zydelig®	Copiktra [®]	Aliqopa [®]
ΡΙ3Κδ	0.8 (n = 3)	2	1	0.7
PI3Kγ (fold vs. PI3Kδ)	114 (142x)	104 <mark>(52x)</mark>	2 (2X)	6.4 (9x)
PI3K α (fold vs. PI3K δ)	>1,000 (>1,250x)	866 <mark>(433x)</mark>	143 (143x)	0.5 (1X)
PI3Kδ human <u>whole blood</u> CD63+	3	14	15	n/a
PI3Kβ (fold vs. PI3Kδ)	87 <mark>(109x)</mark>	293 (147x)	8 (8X)	3.7 (5x)

[1] AbbVie ended collaboration with Infinity in June 2016 following Phase II results in indolent non-Hodgkin's lymphoma. Duvelisib now licensed to Verastem; [2] Accelerated approval was granted based on ORR, and continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trials.








Epitinib (EGFR), Theliatinib (EGFRwt) & HMPL-453 (FGFR) Aim to establish proof-of-concept


Epitinib – 70% response in NSCLC w/ brain mets^[1] Unmet medical need. Investment case under review.



1. Phase Ib ^[1] – epitinib monotherapy in EGFRm+ NSCLC patients – <u>efficacy in lung</u> in-line with Iressa[®]/Tarceva[®].



2. Phase Ib ^[1] - solid/durable <u>efficacy in brain</u> in EGFRm+ NSCLC patients with measurable brain mets (>10mm).



[1] EGFR tyrosine kinase inhibitor treatment naïve patients, Dose expansion stage - data cut-off September 20, 2016; [2] Li B, Bao YC, Chen B, *et al.* Therapy for non-small cell lung cancer patients with brain metastasis. Chinese-German J Clin Oncol, 2014, 13: 483-488; * Unconfirmed PR, due to no further assessment at cut-off date; # Includes both confirmed PRs; ^ MET amplification/high expression identified.



Epitinib - Safe & well tolerated

3. Epitinib well tolerated by patients^[1] w/advanced solid tumors. Safety profile is consistent with that of approved EGFR-TKIs (e.g. Iressa[®]/ Tarceva[®]).

Dose Escalation Stage (n=35*) (Drug related AEs reported >10%)			Dose Expansion Stage (n=37) (Drug related AEs reported >10%)		
160mg QD dose	All Grades n (%)	Grade 3/4 n (%)	160mg QD dose	All Grades n (%)	Grade 3/4 n (%)
Skin rash	21 (60.0%)	1 (2.9%)	Skin rash	31 (83.8%)	2 (5.4%)
Diarrhea	12 (34.3%)	-	Hyper-pigmentation	18 (48.6%)	1 (2.7%)
AST increase	12 (34.3%)	1 (2.9%)	ALT increase	15 (40.5%)	7 (18.9%)
ALT increase	11 (31.4%)	1 (2.9%)	AST increase	15 (40.5%)	4 (10.8%)
Total bilirubin increase	10 (28.6%)	2 (5.7%)	ASP increase	11 (29.7%)	1 (2.7%)
Stomatitis	5 (14.3%)	-	Diarrhea	10 (27.0%)	-
Exfoliative dermatitis	5 (14.3%)	-	Proteinuria	10 (27.0%)	-
Pruritus	5 (14.3%)	-	Total bilirubin increase	9 (24.3%)	1 (2.7%)
Hyper-pigmentation	4 (11.4%)	-	Hyperuricemia	9 (24.3%)	2 (5.4%)
Gamma-GGT increase	4 (11.4%)	2 (5.7%)	Gamma-GGT increase	7 (18.9%)	4 (10.8%)
Conjugated bilirubin	4 (11.4%)	1 (2.9%)	Stomatitis	6 (16.2%)	-

- 4. EGFR gene amplified Glioblastoma (primary brain tumors):
- Phase Ib/II proof-of-concept underway.

CASE STUDY – EGFR-TKI naïve patient

- Male, 46, diagnosed with Stage IV NSCLC adenocarcinoma (Exon21)
- Metastases in the brain, meninges, & bone
- 1st-line chemo naïve
- 120mg QD dosage
- 25 weeks (177 days) on treatment with clear response in multiple measurable (>10mm diameter) brain lesions



171223 7/17/2017 4:47 PM





Theliatinib Potent & highly selective TKI – strong affinity to EGFRwt kinase




1. Major unmet medical need for wild-type EGFR activation tumors.

- EGFR TKIs are less effective in solid tumors with wild-type EGFR activation (gene amplification & protein over expression).
- Ph.Ib study in esophageal cancer short-term response & stable disease observed. Does not warrant continued development as monotherapy. Consider potential immunotherapy combo.

Tumor Types	Wild-type: Gene Amplification	Wild-type: Over Expression	Mutations Iressa®, Tarceva®
NSCLC	29%	62%	10-30%
Esophagus	8-30%	30-90%	12% (esophageal adenocarcinoma)
Stomach	29%	44-52%	<5%
Glioblastoma	36-51%	54-66%	27-54% (EGFR variant III)
Colorectal	4.5%	53%	8%
Head and neck	10-30%	66-84%	42% (EGFR variant III)
			MAbs approved: Erbitux®, Vectibix®

2. Superior anti-tumor activity of theliatinib in pre-clinical studies with wild-type EGFR.


- 5-10-fold more potent than Tarceva[®].
- Sustained target occupancy.



CASE STUDY - EGFR protein over expression

- May 4, 2016: Man, 62, stage IV esophageal squamous cell cancer cT3N0M1with liver metastasis. High protein overexpression - EGFR IHC local test: >75% of tumor cells 3+.
- May 4 to Sep 23, 2016: nimotuzumab/placebo + paclitaxel + cisplatin 6 cycles with best tumor response: PD.
- Oct 11, 2016: began theliatinib 400mg daily.
- Dec 12, 2016: Cycle 3 Day 1 (C3D1) tumor assessment: Target lesion (liver metastasis) shrank -33% (36mm to 23mm diameter) unconfirmed PR.
- Jan 23, 2017: Withdrew from study due to AEs Gr 1 (diarrhea/pruritus/dental ulcer), Gr 2 (epifolliculitis/dermatitis).






KIs = tyrosine kinase inhibitors; MAbs = monoclonal antibodies. [1] GLOBOCAN 2012 (http://globocan.iarc.fr/) and Chen W et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66:115-132

HMPL-453 – Phase I in China ongoing Designed as best-in-class FGFR1/2/3 inhibitor



1. FGFR genetic alterations are oncogenic drivers.

- FGF/FGFR signaling normally involved in embryonic development, tissue repair, angiogenesis, neuroendocrine and metabolism homeostasis.
- Multiple oncogenic driver genetic alterations in FGFR pathway: gene amplification, mutation, translocation, fusion, splicing, etc.



2. FGFR – diverse & complicated genetic changes with multiple tumor types harboring low incidence.

	Gene amplification	Gene translocation	Gene mutation
FGFR1	Lung squamous (7~15%) H&N squamous (10~17%) Esophageal squamous (9%) Breast (10~15%)	Lung squamous (n/a) Glioblastoma (n/a) Myeloproliferative syndrome (n/a) Breast (n/a)	Gastric (4%) Pilocytic astrocytoma (5~8%)
FGFR2	Gastric (5∽10%) Breast (4%)	Intra-hepatic biliary tract cancer (cholangiocarcinoma) (14%) Breast (n/a)	Endometrial (12~14%) Lung squamous (5%)
FGFR3	Bladder (n/a) Salivary adenoid cystic (n/a)	Bladder (3~6%); Lung squamous (3%); Glioblastoma (3%) Myeloma (15~20%)	Bladder (60~80% NMIBC; 15~20 MIBC) Cervical (5%)







Non-Consolidated Joint Ventures

Chi-Med Subsidiaries

Hutchison Hain Organic ("HHO")

Health Related Consumer Prods.

H1 2019: \$10.3m (H1 2018: \$14.2m)


Partner: Hain Celestial Group

Revenue:

Chi-Med Group Structure - Major Entities

Chi-Med Group Level

Revenues - H1 2019; \$102.2m (H1 2018; \$102.2m)



Revenue:

Hutchison BYS Chinese Med. ("HBYS")

Partner: Guangzhou Pharma Holdings

H1 2019: \$118.0m (H1 2018: \$119.0m)

Over-the-counter Drugs ("OTC")

Innovation Platform


Revenue - H1 2019: \$12.0m (H1 2018: \$13.6m) Net Loss Attributable to Chi-Med - H1 2019: -\$63.8m (H1 2018: -\$52.9m)

Hutchison MediPharma ("HMP") Oncology/Immunology Drug R&D

Revenue: H1 2019: \$12.0m (H1 2018: \$13.6m)

FY2019 H1 Inter-group cash flow \$237.3m cash (Jun 30, 2019); \$146.3m in undrawn bank facilities





[1] Others represent changes in working capital, capital expenditure spending and other non-cash items; [2] No capital injection to NSP and no service income received from NSP; [3] Including research & development cost and general & admin. expenses; [4] Share of NSP operating loss; [5] Please see appendix "Non-GAAP Financial Measures and Reconciliation" for a Reconciliation of GAAP to adjusted research and development expenses; [6] Including \$153.9m short-term investment (deposits over 3 months) as at June 30, 2019.

110

(US\$ millions)

Non-GAAP Financial Measures and Reconciliation (1/3)



Reconciliation of Adjusted Group net cash flows and Adjusted Group net cash flows excluding financing activities:

	Jun 30, 2019	2019 Current Guidance	2019 Previous Guidance
Cash and cash equivalents and short-term investments at end period	237.3	180-210 [1]	150-180 [1]
Less: cash and cash equivalents and short-term investments at beginning of year	(301.0)	(300)	(300)
Adjusted Group net cash flows	(63.7)	(90) - (120)	(120) - (150)
Add: Net cash used in financing activities for the period	29.5	_ [1]	_ [1]
Adjusted Group net cash flows excluding financing activities	(34.2)	(90) - (120)	(120) - (150)

Reconciliation of Adjusted Research and Development Expenses:

	H1 2018	H1 2019
Segment operating loss – Innovation Platform	(53.1)	(63.9)
Less: Segment revenue from external customers – Innovation Platform	(13.6)	(12.0)
Add: Costs of goods & service – third parties	_	1.4
Adjusted R&D expenses	(66.7)	(74.5)

[1] For the purposes of this reconciliation, 2019 guidance for net cash used in or generated from financing activities for the year is not provided and as such, cash and cash equivalents and short-term investments at the end of year excludes the effect of any net cash used in or generated from financing activities for the year.

Non-GAAP Financial Measures and Reconciliation (2/3)

Reconciliation of GAAP growth to CER growth

	Six Month	ns Ended	Gr	owth Amoun	t		Growth %	
\$'Million (except %)	June 30, 2019	June 30, 2018	Actual	at CER	Exchange effects	Actual growth %	CER growth %	Exchange effect %
Consolidated sales	102.2	102.2	-	5.1	(5.1)	0%	5%	-5%
Commercial Platform	90.2	88.6	1.6	6.4	(4.8)	2%	7%	-5%
 Prescription Drugs subsidiary 	72.6	68.0	4.6	9.1	(4.5)	7%	13%	-6%
— Consumer Health subsidiaries	17.6	20.6	(3.0)	(2.7)	(0.3)	-15%	-13%	-2%
Non-consolidated joint venture sales	276.9	271.7	5.2	22.3	(17.1)	2%	8%	-6%
— SHPL	158.9	152.7	6.2	15.8	(9.6)	4%	10%	-6%
— HBYS	118.0	119.0	(1.0)	6.5	(7.5)	-1%	5%	-6%
Total Commercial Platform (Non-GAAP)	367.1	360.3	6.8	28.7	(21.9)	2%	8%	6%
Consolidated net income attributable to Chi- Med	(45.4)	(32.7)	(12.7)	(15.6)	2.9	-39%	-48%	9%
Innovation Platform	(63.8)	(52.9)	(10.9)	(15.4)	4.5	-21%	-29%	8%
Commercial Platform	27.7	26.9	0.8	2.4	(1.6)	3%	9%	-6%
 Prescription Drugs 	21.8	20.8	1.0	2.3	(1.3)	5%	11%	-6%
— Consumer Health	5.9	6.1	(0.2)	0.1	(0.3)	-4%	2%	-6%
Sales of SXBX pill	141.0	129.8	11.2	19.7	(8.5)	9%	15%	-6%

Non-GAAP Financial Measures and Reconciliation (3/3)



Reconciliation of Non-GAAP Sales and Non-GAAP Net (loss)/income after tax^[1]

Prescription Drugs: includes our Consolidated subsidiary (Hutchison Sinopharm) and Non-consolidated joint venture (SHPL);

Consumer Health: includes our Consolidated subsidiaries (HHO, HHL and HCP) and Non-consolidated joint venture (HBYS).

					IFF	RS								US GA	AAP				H1'18- H1'19
(US\$ millions)	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	H1'18	H1'19	Growth
Sales (Non-GAAP)	21.9	27.9	65.1	101.4	119.0	155.8	197.0	236.4	278.6	360.7	402.3	465.4	518.9	627.4	677.2	664.4	360.3	367.1	2%
Prescription Drugs	17.2	21.8	23.3	23.2	28.1	39.5	54.4	71.2	92.4	116.5	138.2	204.9	286.6	372.3	411.0	408.5	220.7	231.5	5%
- Consolidated subsidiary	-	-	-	-	-	-	-	-	-	-	-	50.2	105.5	149.9	166.4	132.8	68.0	72.6	7%
- Non-consolidated joint venture	17.2	21.8	23.3	23.2	28.1	<i>39.5</i>	54.4	71.2	92.4	116.5	138.2	154.7	181.1	222.4	244.6	275.7	152.7	158.9	4%
Consumer Health	4.7	6.1	41.8	78.2	90.9	116.3	142.6	165.2	186.2	244.2	264.1	260.5	232.3	255.1	266.2	255.9	139.6	135.6	-3%
- Consolidated subsidiaries	4.7	6.1	9.3	8.9	3.7	5.5	7.0	14.1	14.9	15.5	16.5	16.8	20.7	31.0	38.8	40.1	20.6	17.6	-15%
- Non-consolidated joint venture	-	-	32.5	69.3	87.2	110.8	135.6	151.1	171.3	228.7	247.6	243.7	211.6	224.1	227.4	215.8	119.0	118.0	-1%
Total Sales Growth	n/a	27%	133%	56%	17%	31%	26%	20%	18%	29%	n/a	16%	11%	21%	8%	-2%		2%	
- GuanBao divested in Sept'2017	-	-	-	-	-	-	-	-	(11.4)	(50.5)	(51.6)	(49.7)	(40.7)	(45.0)	(38.6)	0.0	0.0	0.0	n/a
Adjusted Consumer Health	4.7	6.1	41.8	78.2	90.9	116.3	142.6	165.2	174.8	193.7	212.5	210.8	191.6	210.1	227.6	255.9	139.6	135.6	-3%
- Adjusted Non-consolidated joint venture	0.0	-	32.5	69.3	87.2	110.8	135.6	151.1	1 <i>59.9</i>	178.2	196.0	194.0	1 <i>70.9</i>	1 <i>79.</i> 1	188.8	215.8	119.0	118.0	-1%
Adjusted Sales (Non-GAAP)	21.9	27.9	65.1	101.4	119.0	155.8	197.0	236.4	267.2	310.2	350.7	415.7	478.2	582.4	638.6	664.4	360.3	367.1	2%
Total Adjusted Sales Growth	n/a	27%	133%	56%	17%	31%	26%	20%	13%	16%	13%	19%	15%	22%	10%	4%		2%	
Net (loss)/income after tax (Non-GAAP)	(10.7)	(3.6)	2.2	6.7	11.2	14.7	21.5	27.9	30.1	33.1	39.7	48.8	54.1	63.3 [B] 77.3 [4]	83.6	55.1	57.0	3%
Prescription Drugs	(0.4)	1.3	1.9	1.3	1.9	2.8	6.0	11.9	14.2	17.7	22.4	26.5	31.9	41.4	53.0	63.9	41.5	43.7	5%
- Consolidated subsidiary	-	-	-	-	-	-	-	-	-	-	-	0.1	0.6	1.6	2.4	4.1	2.7	1.6	-41%
- Non-consolidated joint venture	(0.4)	1.3	1.9	1.3	1.9	2.8	6.0	11.9	14.2	17.7	22.4	26.4	31.3	<i>39.8</i>	50.6	<i>59.8</i>	38.8	42.1	9%
Consumer Health	(10.3)	(4.9)	0.3	5.4	9.3	11.9	15.5	16.0	15.9	15.4	17.3	22.3	22.2	21.9	24.3	19.7	13.6	13.3	-2%
- Consolidated subsidiaries	(10.3)	(4.9)	(2.9)	(2.4)	0.2	-	0.8	1.0	(0.4)	(1.1)	0.1	1.5	0.8	1.5	3.5	2.8	1.6	1.1	-29%
- Non-consolidated joint venture	-	-	3.2	7.8	9.1	11.9	14.7	15.0	16.3	16.5	17.2	20.8	21.4	20.4	20.8	16.9	12.0	12.2	2%
% Margin	-48.9%	-12.9%	3.4%	6.6%	9.4%	9.4%	10.9%	11.8%	10.8%	9.2%	9.9%	10.5%	10.4%	10.1%	11.4%	12.6%	15.3%	15.5%	
Net (loss)/income attrib. to Chi-Med	(5.7)	(3.7)	(0.5)	1.2	4.5 [2]	5.9[2]	9.3[2]	12.6 [2]	13.6 🕰	14.6[2]	18.2[2	22.8 [2]	25.2[2]	29.9	37.5[4]	41.4	26.9	27.7	3%
Prescription Drugs	(0.2)	0.6	1.0	0.7	0.9	1.4	3.0	5.9	7.1	8.8	11.2	13.2	15.9	20.7	26.5	32.1	20.8	21.8	5%
Consumer Health	(5.5)	(4.3)	(1.5)	0.5	3.6	4.5	6.3	6.7	6.5	5.8	7.0	9.6	9.3	9.2	11.0	9.3	6.1	5.9	-4%
Net (loss)/income attrib. to Chi-Med growth	n/a	-35%	-86%	340%	275%	31%	58%	35%	8%	7%	n/a	26%	10%	19%	25%	10%		3%	

[1] 2003-2006 incl. disco. operation;
 [2] Continuing Operations;
 [3] Excludes the land compensation in SHPL of \$80.8 million from net income after tax and \$40.4 million from net income attributable to Chi-Med for 2016;
 [4] Excludes SHPL's R&D related subsidies of \$5.0 million from net income after tax and \$2.5 million from net income attributable to Chi-Med for 2017.



China Commercial Platform has substantial value

- Chi-Med's Commercial Platform continues to perform well relative to our peer group.
- The market value, based on China Pharma median PE multiples is approximately \$1.8 billion.^[1] Given our share in the JVs, Chi-Med's share of this value is approximately \$0.9 billion.

			NET SALES			NET INCO	OME		VALUATION [4]
	Code	2017 Jan-Dec	2018 Jan-Dec	FY17-18 Growth	2017 Jan-Dec	2018 Jan-Dec	FY17-18 Growth	FY2018 Margin	Market Cap.	P/E
CHI-MED Commercial Platform Subsidiaries/JVs ^[2]		638.6 ^[3]	664.4	4%	77.3	83.6	8%	13%	n/a	n/a
Li Zhu Pharma	000513	1,292.6	1,342.5	4%	124.2	179.0	44%	13%	3,590	16
Shandong Dong E E Jiao	000423	1,117.0	1,111.9	0%	309.7	316.2	2%	28%	3,384	12
Kunming Pharma	600422	886.7	1,076.1	21%	50.8	51.8	2%	5%	1,247	23
Zhejiang Kang En Bai Pharma	600572	802.1	1,028.3	28%	110.6	122.5	11%	12%	2,655	24
Tianjin Zhong Xin Pharma	600329	862.0	963.4	12%	71.7	86.0	20%	9%	1,560	18
Zhangzhou Pien Tze Huang	600436	562.7	722.1	28%	118.2	171.0	45%	24%	9,654	52
Jiangsu Kang Yuan	600557	496.2	579.4	17%	57.3	66.3	16%	11%	1,333	20
Zhuzhou Qian Jin Pharma	600479	482.2	504.3	5%	37.4	45.8	23%	9%	618	15
Jiu Zhi Tang	000989	581.3	473.1	-19%	109.3	49.0	-55%	10%	1,113	27
Wuhan Jian Min Pharma	600976	410.8	327.5	-20%	13.9	12.3	-11%	4%	356	29
Peer Group Median (10 Comps. excl. Chi-Med)		691.7	842.8	22%	90.5	76.2	-16%	9%	1,446	21
All 61 Listed whina Pharma. Companies Median		515.1	579.4	12%	50.8	49.6	-2%	9%	1,247	21

Peer Group: 10 companies (excl. Chi-Med) selected as ALL listed and profitable mainland Chinese OTC/RX pharma manufacturing companies, with a focus on similar product types, and 2018 Net Sales in the ~\$300-1,400 million range.

(US\$ millions)

Source: Company data, Deutsche Bank, FactSet

[1] Peer group/China Pharma multiple of 21x 2018 actual Net income after tax of \$83.6 million; [2] Total aggregate PRC domestic results of Chi-Med's 6 Commercial Platform companies (HBYS, SHPL, Hutchison Sinopharm, HHO, HHL & HCPL); [3] Excluding Guanbao (divested); [4] Market Capitalization and Price Earnings Ratios as at **July 26, 2019**: Trailing Twelve Month PE weighted averaged based on market capitalization.

National Reimbursement Drug List Pricing ("NRDL") July'17 update – 15 new drugs in oncology^[1] added to NRDL



		U	nit Pricing (US\$) [3]		Approximate Mon	thly Pricing (U	S\$) ^[3]	
Brand (generic)	Company	Dosage	Avg. Tender	Reimbursed	Δ %	Dosage	Avg. Tender	Reimbursed	Indication coverage
Herceptin® (trastuzumab)	Roche	440mg:20ml	\$3,298.81	\$1,125.93	-66%	Breast: 4mg/kg wk 1, 2mg/kg weekly. ^[2]	\$4,500	\$1,540	Breast: Her2+; Her2+ meta. Her2+ late-stage meta. gastric.
Avastin® (bevacizumab)	Roche	100mg:4ml	\$772.74	\$296.00	-62%	10mg/kg 0.2W.	\$11,590	\$4,440	Late-stage meta. CRC or advanced non-squamous NSCLC.
TheraCIM ^{®[4]} (nimotuzumab)	Biotech Pharma	50mg:10ml	\$435.26	\$251.85	-42%	100mg weekly.	\$3,730	\$2,160	Combo with radiotherapy for EGFR+ Stage III/IV nasopharyngeal carcinoma.
Rituxan® (rituximab)	Roche	500mg:50ml ^[2]	\$2,544.74	\$1,228.15	-52%	375 mg/m² weekly.	\$13,090	\$6,320	Restorative or resistant follicular central type lym.; CD20+ stage III-IV follicular NHL, CD20+ DLBCL.
Tarceva® (erlotinib)	Roche	150mg ^[2]	\$68.15	\$28.89	-58%	150mg QD.	\$2,040	\$870	Advanced NSCLC with limited EGFR gene mutation.
Nexavar® (sorafenib)	Bayer	0.2g	\$60.44	\$30.07	-50%	400mg BID.	\$7,250	\$3,610	Unresectable RCC. Unresectable HCC. meta. Diff. thyroid after radio-iodine therapy.
Tykerb® (lapatinib)	GSK	250mg	\$17.63	\$10.37	-41%	1,500mg QD.	\$3,170	\$1,870	Adv./meta. breast cancer with Her2 O/E, after anthracycline, paclitaxel, trastuzumab.
AiTan® (apatinib)	Hengrui	425mg ^[2]	\$47.85	\$30.22	-37%	850mg QD.	\$2,870	\$1,810	3L gastric adenocarcinoma or esophageal junction with adenocarcinoma.
Velcade® (bortezomib)	L&L	3.5mg ^[2]	\$1,873.78	\$906.07	-52%	1.3mg/m² quartic every 3 wks.	\$6,360	\$3,080	Myeloma; recurring or refractory mantle cell lymphoma.
EnDu® (rh-endostatin)	Simcere	15mg	\$132.15	\$93.33	-29%	7.5mg/m² iv QD 2-wks- on / 1-week-off.	\$2,110	\$1,490	Late-stage NSCLC.
Epidaza® (chidamide)	Chipscreen	5mg	\$81.48	\$57.04	-30%	30mg QD, 2x per wk.	\$4,190	\$2,930	2L+ Recurring or refractory peripheral T-cell lymphoma (PTCL).
Zytiga® (abiraterone)	1%I	250mg	\$45.63	\$21.48	-53%	1,000mg QD.	\$5,480	\$2,580	Metastatic or ovariectomized prostate cancer.
Faslodex® (fulvestrant)	AstraZeneca	250mg:5ml	\$806.81	\$355.56	-56%	500mg per month.	\$1,610	\$710	Advanced ER/PR+ breast can., failing aromatase inhibitor.
Afinitor® (everolimus)	Novartis	5mg ^[2]	\$36.44	\$21.93	-40%	10mg QD.	\$2,190	\$1,320	Adv. RCC after sunitinib or sorafenib. Adv./meta. pancreatic NETs. Tuberous sclerosis with renal angiomyolipoma.
Revlimid (lenalidomide)	Celgene	25mg ^[2]	\$413.93	\$163.26	-61%	25mg QD 3-wks-on / 1-wk-off.	\$9,310	\$3,670	2L+ Recurring myeloma.

Source: Ministry of Human Resources and Social Security (MOHRSS); Yaozhi; BofA Merrill Lynch Global Research.

[1] Excluding 3 botanical oncology drugs; [2] Reference SKU or reference recommended dosage for monthly pricing calculation; [3] Calculation assumes an exchange rate of CN¥6.75 per US\$1; [4] Marketed as Tai Xin Sheng® in China.

National Reimbursement Drug List Pricing ("NRDL") Oct'18 update – 17 new drugs in oncology added to NRDL



			Unit Pricing (US\$) ^[2]		Approximate Monthly P	Pricing (US\$) ^[2]				
Brand (generic)	Company	Dosage	Avg. Tender	Reimbursed	Δ %	Dosage ^[1]	Avg. Tender	Reimbursed	Indication coverage		
Focus V [®] (anlotinib)	Sino Biopharn	n 12mg	\$127	\$70	-45%	12mg QD (2 wks-on/1-wk-off)	\$1,783	\$981	3L NSCLC		
Oncaspar® (pegaspargase)	Hengrui	5ml:3750 IU	\$560	\$429	-23%	\leq 2ml every 14 days	\$1,231	\$943	1L ALL		
Vidaza [®] (azacitidine)	Celgene	100mg	\$378	\$152	-60%	1 st cycle: 75mg QD for 7 days; 4wk cycle. After 2 cycles increase dose to 100mg, min of 4-6 cycles	\$14,022	\$5,636	Refractory anemia (RA) or RA with ringed sideroblasts (RARS), RA with excess blasts (RAEB / RAEB-T), and chronic myelomonocytic leukemia (CMMoL)		
Inlyta [®] (axitinib)	Pfizer	5mg	\$99	\$30	-70%	5mg BID	\$5,957	\$1,787	2L Advanced renal cell carcinoma		
Tagrisso [®] (osimertinib)	AstraZeneca	80mg	\$253	\$73	-71%	80mg QD	\$7,597	\$2,201	EGFR TKI refractory T790M+ NSCLC		
Ninlaro [®] (ixazomib)	Takeda	4mg	\$3,234	\$710	-78%	4mg on Days 1, 8, 15 (28 day cycle)	\$12,934	\$2,839	2L Multiple myeloma		
Xalkori [®] (crizotinib)	Pfizer	250mg	\$123	\$37	-70%	250mg BID	\$7,407	\$2,245	Locally adv. or meta. ALK+ or ROS1+ NSCLC		
Gilotrif [®] (afatinib)	Boehringer	40mg	\$116	\$29	-75%	40mg QD	\$3,483	\$863	NSCLC with EGFR		
Tasigna [®] (nilotinib)	Novartis	200mg	\$39	\$14	-65%	400mg BID	\$4,645	\$1,635	CML		
Votrient [®] (pazopanib)	Novartis	200mg	\$66	\$23	-65%	800mg QD	\$7,891	\$2,348	RCC		
Sutent [®] (sunitinib)	Pfizer	12.5mg	\$49	\$22	-55%	GIST & RCC: 50mg QD pNET: 37.5mg QD	\$5,544 \$4,455	\$2,498 \$2,007	RCC, GIST, pNET		
Stivarga [®] (regorafenib)	Bayer	40mg	\$52	\$28	-46%	160mg QD, 3-wks-on/1-wk-off *	\$4,368	\$2,352	Meta. CRC, GIST, HCC		
Zykadia [®] (certinib)	Novartis	150mg	\$108	\$28	-74%	450mg QD	\$9,699	\$2,564	NSCLC		
Zelboraf [®] (vemurafenib)	Roche	240mg	\$30	\$16	-47%	960mg BID	\$7,252	\$2,369	Melanoma		
Erbitux [®] (cetuximab)	Merck	100mg	\$571	\$186	-67%	400mg/m2 initial dose, 250mg weekly	\$10,446	\$3,074	Colorectal cancer, head and neck cancer		
Sandostatin LAR [®] (octreotide)	Novartis	20mg	\$1,169	\$835	-29%	20mg Q4W	\$1,169	\$835	GEP-NENs		
Imbruvica [®] (ibrutinib)	INI	140mg	\$78	\$27	-65%	MCL: 560mg QD CLL & WM: 420mg QD	\$9,324 \$6,993	\$3,263 \$2,447	MCL, CLL/SLL		

Source: Ministry of Human Resources and Social Security (MOHRSS); Yaozhi; China Merchants Securities Research; Citi Global Research.

[1] Reference SKU or reference recommended dosage for monthly pricing calculation; [2] Calculation assumes an exchange rate of CN¥6.95 per US\$1.

* Price amended to account for 3-weeks on, 1 week off regimen.

National Reimbursement Drug List Pricing ("NRDL") Nov'19 update - 8 new and 9 renewed drugs in oncology^[1]



			Unit Pricing ((US\$) ^[3]		Approximate Mo	nthly Pricing (l	JS\$) ^[3]	
Brand (generic)	Company	Dosage	Avg. Tender	Reimbursed	Δ %	Dosage	Avg. Tender	Reimbursed	Indication coverage
Elunate [®] (fruquintinib)	Chi-Med	5mg	\$149	\$53.77	-64%	5mg QD 3wks/1wk-off.	\$3,350	\$1,210	Metastatic colorectal cancer, 3L
Tyvyt [®] (sintilimab)	Innovent	10ml	\$1,114	\$404.41	-64%				Classical Hodgkin's lymphoma, 3L
Saiweijian [®] (raltitrexed)	Sino Biopharm	2mg	\$234	\$95.16	-59%				colorectal cancer, 5-FU intolerable
Alecensa [®] (alectinib)	Roche			Undisclosed					NSCLC, ALK+
Lynparza [®] (olaparib)	AstraZeneca			Undisclosed					Epithelial ovarian, fallopian tube, or peritoneal cancer
Airuini [®] (pyrotinib)	Hengrui			Undisclosed					Breast cancer, HER2+, 2L
Perjeta [®] (pertuzumab)	Roche			Undisclosed					Breast cancer, HER2+, neoadjuvant
Jakafi [®] (ruxolitinib)	Incyte / Novartis			Undisclosed					PMF, PPV-MF, PET-MF

			Unit Pricing	(US\$) ^[3]		Approximate Monthly Pi	ricing (US\$)	[3]	
Brand (generic)	Company	Dosage	'17 NRDL	'19 NRDL	$\Delta\%$	Dosage	'17 NRDL	'19 NRDL	Indication coverage
AiTan® (apatinib)	Hengrui	425mg ^[2]	\$29.03	\$24.56	-15%	850mg QD.	\$1,740	\$1,470	3L gastric adenocarcinoma or GEJ with adenocarcinoma.
EnDu® (rh-endostatin)	Simcere	15mg	\$89.62	\$69.70	-22%	7.5mg/m² iv QD 2wks/1wk-off.	\$1,430	\$1,120	Late-stage NSCLC.
Epidaza® (chidamide)	Chipscreen	5mg	\$54.77	\$48.79	-11%	30mg QD, 2x per wk.	\$2,820	\$2,510	2L+ Recurring or refractory peripheral T-cell lymph. (PTCL).
Avastin® (bevacizumab)	Roche			Undisclosed					Late-stage meta. CRC or advanced non-squamous NSCLC.
TheraCIM ^{®[4]} (nimotuzumab)	Biotech			Undisclosed					Combo with RT for EGFR+ III/IV nasopharyngeal carcinoma.
Tarceva® (erlotinib)	Roche			Undisclosed					Advanced NSCLC with limited EGFR gene mutation.
Herceptin® (trastuzumab)	Roche			Undisclosed					Breast: Her2+; Her2+ meta. Her2+ late-stage meta. gastric.
Afinitor [®] (everolimus)	Novartis			Undisclosed					RCC after sunitinib or sorafenib. Pancreatic NETs. TSRA.
Nexavar® (sorafenib)	Bayer			Undisclosed					RCC or HCC. meta. diff. thyroid after radio-iodine therapy.

Source: National Healthcare Security Administration (NHSA); Goldman Sachs equity research.

[1] Excluding botanical oncology drugs; [2] Reference SKU or reference recommended dosage for monthly pricing calculation; [3] Calculation assumes an exchange rate of CN¥7.03 per US\$1; [4] Marketed as Tai Xin Sheng[®] in China.





HUTCHISON CHINA MEDITECH

Thank you